Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 618. Отображено 128.
08-08-2017 дата публикации

5′-end derivatives

Номер: US0009725479B2

The present invention provides compounds of formula (1). Another aspect of the invention relates to a method of inhibiting the expression of a gene in call, the method comprising (a) contacting an oligonucleotide of the invention with the cell; and (b) maintaining the cell from step (a) for a time sufficient to obtain degradation of the mRNA of the target gene.

Подробнее
09-02-2017 дата публикации

OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS

Номер: US20170037402A1
Принадлежит: Regulus Therapeutics Inc.

Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided. 1. (canceled)2. A method of inhibiting the activity , function , or amount of miR-17 (SEQ ID NO: 204) , comprising contacting a cell with a compound comprising a modified oligonucleotide , wherein:the modified oligonucleotide consists of 8, 9, 10, 11, or 12 linked monomeric subunits;each monomeric subunit of the modified oligonucleotide comprises a modified sugar moiety; andthe modified oligonucleotide is complementary to miR-17 with no more than one mismatch.3. The method of wherein the modified oligonucleotide consists of 8 monomeric subunits.4. The method of wherein the modified oligonucleotide consists of 9 monomeric subunits.5. The method of wherein the modified oligonucleotide consists of 10 monomeric subunits.6. The method of wherein the modified oligonucleotide consists of 11 monomeric subunits.7. The method of wherein the modified oligonucleotide consists of 12 monomeric subunits.8. The method of claim 2 , wherein each modified sugar moiety is independently selected from a 2′-F sugar moiety claim 2 , a 2′-O-methyl sugar moiety claim 2 , a 2′-O-methoxyethyl sugar moiety claim 2 , and a bicyclic sugar moiety.9. The method of claim 8 , wherein the bicyclic sugar moiety has a 4′-CH—O-2′ bridge.10. The method of claim 2 , wherein the modified oligonucleotide comprises at least one modified internucleoside linkage.11. The method of claim 10 , wherein the modified internucleoside linkage is a phosphorothioate linkage.12. The method of claim 2 , wherein each internucleoside linkage of the modified oligonucleotide is a phosphorothioate linkage.13. The ...

Подробнее
07-11-2012 дата публикации

6-modified bicyclic nucleic acid analogs

Номер: CN102766630A
Принадлежит:

The present invention provides 6-modified bicyclic nucleoside analogs and oligomeric compounds comprising these nucleoside analogs. In preferred embodiments the nucleoside analogs have either(R) or (S)-chirality at the 6-position. These bicyclicnucleoside analogs are useful for enhancing properties of oligomeric compounds including nuclease resistance.

Подробнее
05-09-2017 дата публикации

Gapped oligomeric compounds comprising 5′-modified deoxyribonucleosides in the gap and uses thereof

Номер: US0009752142B2

The present invention provides gapped oligomeric compounds comprising at least one 5′-substituted P-D-2′-deoxyribonucleoside in the gap region. Certain such gapped oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited to, nucleic acids in a cell. The oligomeric compounds provided herein have improved properties such as selectivity, potency and improved proinflammatory profile. In certain embodiments, hybridization results in modulation of the amount of activity or expression of the target nucleic acid in a cell.

Подробнее
11-04-2017 дата публикации

Compounds and methods for modulating gene expression

Номер: US0009617540B2

The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.

Подробнее
24-01-2017 дата публикации

Antisense compounds

Номер: US0009550988B2

Provided herein are gapmer oligomeric compounds for reduction of target RNA in vivo comprising different nucleotide modifications within one or both wing regions. Also provided are methods of using such oligomeric compounds, including use in animals. In certain embodiments, such compound have desirable potency and toxicity characteristics.

Подробнее
26-09-2017 дата публикации

Phosphorous-linked oligomeric compounds and their use in gene modulation

Номер: US0009771578B2

Oligonucleotide compositions comprising first and second oligonucleotides are provided wherein at least a portion of the first oligonucleotide is capable of hybridizing with at least a portion of the second oligonucleotide, at least a portion of the first oligonucleotide is complementary to and capable of hybridizing to a selected target nucleic acid, and at least one of the first or second oligonucleotides includes at least one nucleotide having a modified phosphorous-containing internucleoside linkage. Oligonucleotide/protein compositions are also provided comprising an oligonucleotide complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex (RISC), wherein at least one nucleotide of the oligonucleotide has a modified phosphorous-containing internucleoside linkage.

Подробнее
08-06-2017 дата публикации

COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION

Номер: US20170159055A1
Принадлежит: Ionis Pharmaceuticals, Inc.

The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.

Подробнее
16-02-2017 дата публикации

METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS

Номер: US20170043025A1
Принадлежит: Ionis Pharmaceuticals, Inc.

Provided herein are improved methods for the synthesis of reactive conjugate clusters and intermediates used in such methods. In particular, improvements are provided that enhance the synthesis of reactive conjugate clusters by reducing the number of synthetic steps required. The reactive conjugate clusters prepared using the improved methods don't include any transacylation impurities that are formed using existing methods. The improved methods also provide an increase in overall yield and a cost benefit over existing methods. 2. The method of wherein each E is Cto Calkyl.3. The method of any of wherein each E is a single bond.4. The method of wherein G is Cto Calkyl optionally including one or more groups selected from —O— claim 1 , —N(H)— and C(═O).5. The method of wherein G is —C(═O)—(CH)—C(═O)—O—.6. The method of wherein G is single bond.7. (canceled)8. The method of wherein Pgis benzyl.1011-. (canceled)12. The method of wherein m is 3.14. The method of wherein the pentafluorophenyl ester protected branching group is at least about 95% pure.1729-. (canceled)30. The method of wherein the pentafluorophenyl ester protected branching group and about 3.4 equivalents of the functionalized ligand are dissolved in the organic solvent and Pd(OH)/C is added under Hwith stirring at room temperature until completion.31. The method of wherein the organic solvent is acetonitrile claim 1 , ethyl acetate claim 1 , tetrahydrofuran or a mixture thereof.32. The method of wherein the organic solvent is tetrahydrofuran.33. The method of wherein the reactive conjugate cluster is prepared without using column chromatography.3536-. (canceled)37. The method of further comprising treatment of the reactive conjugate cluster with pentafluorophenyl trifluoroacetate to provide a PFP esterified conjugate cluster.38. The method of wherein the PFP esterified conjugate cluster is prepared without using column chromatography.39. The method of wherein the PFP esterified conjugate cluster is ...

Подробнее
25-05-2017 дата публикации

BICYCLIC CARBOCYCLIC NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM

Номер: US20170145409A1
Принадлежит: Ionis Pharmaceuticals, Inc.

The present invention provides novel bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom. Incorporation of one or more of the bicyclic carbocyclic nucleosides into an oligomeric compound is expected to enhance one or more properties of the oligomeric compound. In certain embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in modulation of normal function of the target RNA. In certain embodiments, bicyclic carbocyclic nucleosides are provided as monomers for use as antivirals.

Подробнее
20-09-2016 дата публикации

Oligomeric compounds and compositions for use in modulation of small non-coding RNAS

Номер: US0009447412B2

Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.

Подробнее
09-02-2017 дата публикации

COMPOSITIONS FOR MODULATING SOD-1 EXPRESSION

Номер: US20170037410A1
Принадлежит: Ionis Pharmaceuticals, Inc.

Disclosed herein are antisense compounds and methods for decreasing SOD-1 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate SOD-1 associated diseases, disorders, and conditions. Such SOD-1 associated diseases include amyotrophic sclerosis (ALS). 1. A compound , comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides and having a nucleobase sequence comprising at least 8 , at least 9 , at least 10 , at least 11 , at least 12 , at least 13 , at least 14 , at least 15 , at least 16 , at least 17 , at least 18 , at least 19 , or at least 20 consecutive nucleobases of any of the nucleobase sequences of SEQ ID NOs: 118-1461.2. A compound , comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides and having a nucleobase sequence comprising at least 8 , at least 9 , at least 10 , at least 11 , at least 12 , at least 13 , at least 14 , at least 15 , at least 16 , at least 17 , at least 18 , at least 19 , or at least 20 consecutive nucleobases of any of the nucleobase sequences of SEQ ID NOs:15 , 21 , 23 , 47 , 54 , and 67 , wherein at least one internucleoside linkage is a phosphodiester linkage.3. The compound of claim 1 , wherein the modified oligonucleotide has a mixed backbone.7. The compound of any preceding claim claim 1 , wherein the nucleobase sequence of the modified oligonucleotide is at least 80% claim 1 , at least 81% claim 1 , at least 82% claim 1 , at least 83% claim 1 , at least 84% claim 1 , at least 85% claim 1 , at least 86% claim 1 , at least 87% claim 1 , at least 88% claim 1 , at least 89% claim 1 , at least 90% claim 1 , at least 91% claim 1 , at least 92% claim 1 , at least 93% claim 1 , at least 94% claim 1 , at least 95% claim 1 , at least 96% claim 1 , at least 97% claim 1 , at least 98% claim 1 , at least 99% claim 1 , or 100% complementary to SEQ ID NO: 1 or SEQ ID NO: 2.8. The compound of any preceding claim claim 1 , wherein the ...

Подробнее
13-06-2017 дата публикации

Modulation of hepatitis B virus (HBV) expression

Номер: US0009677076B2

Disclosed herein are antisense compounds and methods for decreasing HBV mRNA, DNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate HBV-related diseases, disorders or conditions.

Подробнее
13-03-2018 дата публикации

Oligomeric compounds comprising bicyclic nucleotides and uses thereof

Номер: US0009914922B2

The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.

Подробнее
30-08-2016 дата публикации

Oligomeric compounds comprising tricyclic nucleosides and methods for their use

Номер: US0009428750B2

The present disclosure provides tricyclic nucleosides, oligomeric compounds comprising at least one of the tricyclic nucleosides and methods of using the oligomeric compounds. The methods provided herein include contacting a cell or administering to an animal at least one of the oligomeric compounds. In certain embodiments, the oligomeric compounds hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.

Подробнее
22-08-2017 дата публикации

Oligomeric compounds and methods

Номер: US0009738895B2

The present invention provides oligomeric compounds and uses thereof. In certain embodiments, such oligomeric compounds are useful as antisense compounds. Certain such antisense compounds are useful as RNase H antisense compounds or as RNAi compounds.

Подробнее
11-05-2017 дата публикации

LINKAGE MODIFIED GAPPED OLIGOMERIC COMPOUNDS AND USES THEREOF

Номер: US20170130224A1
Принадлежит: Ionis Pharmaceuticals, Inc.

The present invention provides gapped oligomeric compounds. More particularly the gapped oligomeric compounds provided herein comprise at least one modified internucleoside linkage in the gap region. Such gapped oligomeric compounds have one or more improved properties such as selectivity, potency, improved toxicity profile and or improved proinflammatory profile. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell. 2. The gapped oligomeric compound of having only one internucleoside linking group of Formula I.3. The gapped oligomeric compound of wherein the internucleoside linking group of Formula I is located between nucleosides 1 and 2 claim 2 , 2 and 3 claim 2 , or 3 and 4 claim 2 , counting from the 5′ gap junction.4. The gapped oligomeric compound of having only two internucleoside linking groups of Formula I.5. The gapped oligomeric compound of wherein the internucleoside linking groups of Formula I are located between nucleosides 1 and 3 claim 4 , or 2 and 4 claim 4 , counting from the 5′ gap junction.6. The gapped oligomeric compound of wherein each internucleoside linking group other than internucleoside linking groups having Formula I is a phosphorothioate internucleoside linking group.7. The gapped oligomeric compound of wherein each monomer subunit comprises a heterocyclic base independently selected from uracil claim 1 , thymine claim 1 , cytosine claim 1 , 4-N-benzoylcytosine claim 1 , 5-methylcytosine claim 1 , 4-N-benzoyl-5-methylcytosine claim 1 , adenine claim 1 , 6-N-benzoyladenine claim 1 , guanine and 2-N-isobutyrylguanine.8. The gapped oligomeric compound of wherein each Q is claim 1 , independently claim 1 , selected from CH claim 1 , C(═O)OH claim 1 , CHC(═O)OH claim 1 , (CH)OCH claim 1 , CH═CH claim 1 , CHCH═CHand ...

Подробнее
21-09-2017 дата публикации

OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS

Номер: US20170268002A1
Принадлежит: Regulus Therapeutics Inc.

Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.

Подробнее
25-05-2017 дата публикации

COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS

Номер: US20170145424A1
Принадлежит: Ionis Pharmaceuticals, Inc.

Provided herein are compositions and methods for non-parenteral delivery of conjugated oligomeric compounds. In certain embodiments, compositions and methods are provided for oral delivery of conjugated oligomeric compounds. In certain embodiments, the oligomeric compounds are conjugated to one or more N-acetylgalactosamines or N-acetylgalactosamine analogues.

Подробнее
15-06-2017 дата публикации

COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION

Номер: US20170166899A1
Принадлежит: IONIS PHARMACEUTICALS, INC.

The present embodiments provide methods, compounds, and compositions for treating, preventing, ameliorating a disease associated with excess growth hormone using antisense compounds oligonucleotides targeted to growth hormone receptor (GHR).

Подробнее
27-06-2017 дата публикации

Bicyclic morpholino compounds and oligomeric compounds prepared therefrom

Номер: US0009688707B2

The present invention provides bicyclic morpholino compounds and oligomeric compounds prepared therefrom. More particularly, incorporation of one or more of the bicyclic morpholino compounds into an oligomeric compound is expected to enhance one or more properties of the oligomeric compound. Such oligomeric compounds can also be included in a double stranded composition. In certain embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.

Подробнее
18-07-2017 дата публикации

Compositions comprising alternating 2′-modified nucleosides for use in gene modulation

Номер: US0009708610B2

The present invention provides compositions comprising at least one oligomeric compound comprising an alternating motif and further include a region that is complementary to a nucleic acid target. The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes. In preferred embodiments the compositions of the present invention hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. The present invention also provides methods for modulating gene expression.

Подробнее
29-06-2017 дата публикации

ANTISENSE COMPOUNDS

Номер: US20170182082A1
Принадлежит: Ionis Pharmaceuticals, Inc.

Provided herein are gapmer oligomeric compounds for reduction of target RNA in vivo comprising different nucleotide modifications within one or both wing regions. Also provided are methods of using such oligomeric compounds, including use in animals. In certain embodiments, such compound have desirable potency and toxicity characteristics.

Подробнее
21-03-2017 дата публикации

Oligomeric compounds and compositions for the use in modulation of micrornas

Номер: US0009598693B2

Compounds, compositions and methods are provided for modulating the levels expression, processing and function of miRNAs. The compositions comprise oligomeric compounds targeted to small non-coding RNAs and miRNAs. The oligomeric compounds possess potent miRNA inhibitory activity, and further exhibit improved therapeutic index. Further provided are methods for selectively modulating miRNA activating in a cell.

Подробнее
16-02-2017 дата публикации

LINKAGE MODIFIED OLIGOMERIC COMPOUNDS

Номер: US20170044526A1
Принадлежит: Ionis Pharmaceuticals, Inc.

The present invention provides oligomeric compounds comprising at least one neutral methoxypropyl phosphonate modified internucleoside linkage. Such oligomeric compounds have one or more improved properties such as selectivity, potency, improved toxicity profile and or improved proinflammatory profile. Such oligomeric compounds have enhanced stability to exposure to base during synthesis. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.

Подробнее
01-12-2016 дата публикации

MODULATION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 (STAT3) EXPRESSION

Номер: US20160348104A1
Принадлежит:

Disclosed herein are antisense compounds and methods for decreasing STAT3 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate hyperproliferative diseases.

Подробнее
03-04-2018 дата публикации

Compositions and methods for modulating HBV expression

Номер: US0009932580B2

Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.

Подробнее
09-08-2016 дата публикации

Cyclohexenyl nucleic acids analogs

Номер: US0009409934B2

The present disclosure describes cyclohexenyl nucleic acid analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, cyclohexenyl nucleic acid analogs are provided, having one or more chiral substituents, that are expected to be useful for enhancing properties of oligomeric compounds including nuclease resistance and binding affinity. In some embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.

Подробнее
29-06-2017 дата публикации

COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION

Номер: US20170183661A1
Принадлежит: Ionis Pharmaceuticals, Inc.

Disclosed herein are antisense compounds and methods for decreasing PKK mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate PKK-associated diseases, disorders, and conditions.

Подробнее
27-03-2018 дата публикации

Linkage modified oligomeric compounds

Номер: US9926556B2

The present invention provides oligomeric compounds comprising at least one neutral methoxypropyl phosphonate modified internucleoside linkage. Such oligomeric compounds have one or more improved properties such as selectivity, potency, improved toxicity profile and or improved proinflammatory profile. Such oligomeric compounds have enhanced stability to exposure to base during synthesis. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.

Подробнее
03-04-2018 дата публикации

Compositions and methods for modulating apolipoprotein C-III expression

Номер: US0009932581B2

Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein C-III (ApoCIII). In certain embodiments, the ApoCIII targeting oligomeric compounds are conjugated to N-Acetylgalactosamine Also disclosed herein are conjugated oligomeric compounds targeting ApoCIII for use in decreasing ApoCIII to treat, prevent, or ameliorate diseases, disorders or conditions related to ApoCIII. Certain diseases, disorders or conditions related to ApoCIII include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.

Подробнее
04-07-2017 дата публикации

Oligomeric compounds comprising bicyclic nucleosides and uses thereof

Номер: US0009695418B2

The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell. In certain embodiments, the present invention provides compounds comprising oligonucleotides. In certain embodiments, such oligonucleotides comprise a region having a gapmer sugar motif. In certain embodiments, oligonucleotides comprise one or more type of modified sugar moieties and/or naturally occurring sugar moieties arranged along an oligonucleotide or region thereof in a defined pattern or sugar modification motif.

Подробнее
16-02-2017 дата публикации

OLIGOMERIC COMPOUNDS COMPRISING ALPHA-BETA-CONSTRAINED NUCLEIC ACID

Номер: US20170044539A1
Принадлежит: Ionis Pharmaceuticals, Inc.

The present disclosure provides oligomeric compounds comprising at least one α-β-constrained nucleic acid as provided herein. More particularly, the α-β-constrained nucleic acid provided herein comprise an optionally modified nucleoside with a phosphorus containing constrained internucleoside linkage such as for example a cyclic phosphate internucleoside linkage. The α-β-constrained nucleic acid provided herein are expected to be useful for enhancing one or more properties of oligomeric compounds they are incorporated into such as for example nuclease resistance. In certain embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. 2. The oligomeric compound of wherein each X is O.3. (canceled)4. The oligomeric compound of wherein each X is CH.57-. (canceled)8. The oligomeric compound of wherein each Z is O.9. (canceled)10. The oligomeric compound of wherein each Z is CH.11. The oligomeric compound of wherein each Z is S.12. The oligomeric compound of wherein each Z is NH or NCH.1315-. (canceled)16. The oligomeric compound of wherein one of each Gand each Gis H and the other of each Gand each Gis claim 1 , independently claim 1 , selected from halogen claim 1 , OCH claim 1 , OCF claim 1 , OCHCH claim 1 , OCHCF claim 1 , OCH—CH═CH claim 1 , O(CH)—OCH claim 1 , O(CH)—O(CH)—N(CH) claim 1 , OCHC(═O)—N(H)CH claim 1 , OCHC(═O)—N(H)—(CH)—N(CH)and OCH—N(H)—C(═NH)NH.1718-. (canceled)19. The oligomeric compound of wherein each Gis O(CH)—OCHand each Gis H.20. The oligomeric compound of wherein each Gand Gis H.21. (canceled)22. The oligomeric compound of wherein each Bx is claim 1 , independently claim 1 , uracil claim 1 , thymine claim 1 , cytosine claim 1 , 4-N-benzoylcytosine claim 1 , 5-methyl-cytosine claim 1 , 4-N-benzoyl-5-methylcytosine claim 1 , adenine claim 1 , 6-N-benzoyladenine claim 1 , guanine or 2-N-isobutyrylguanine.24. The oligomeric compound of wherein each modified ...

Подробнее
20-10-2016 дата публикации

COMPOUNDS AND METHODS FOR MODULATION OF DYSTROPHIA MYOTONICA-PROTEIN KINASE (DMPK) EXPRESSION

Номер: US20160304877A1
Принадлежит: Ionis Pharmaceuticals, Inc.

Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.

Подробнее
12-01-2012 дата публикации

5'-modified bicyclic nucleic acid analogs

Номер: US20120010393A1
Принадлежит: ISIS PHARMACEUTICALS INC

The present invention provides 5′-modified bicyclic nucleoside analogs and oligomeric compounds comprising at least one of these nucleoside analogs. In preferred embodiments the nucleoside analogs have either (R) or (S)-chirality at the 5′-carbon. These bicyclic nucleoside analogs are useful for enhancing properties of oligomeric compounds including for example enhanced nuclease resistance.

Подробнее
26-01-2012 дата публикации

OLIGOMERIC COMPOUNDS AND METHODS

Номер: US20120021515A1
Принадлежит:

The present invention provides oligomeric compounds and uses thereof. In certain embodiments, such oligomeric compounds are useful as antisense compounds. Certain such antisense compounds are useful as RNase H antisense compounds, as RNAi compounds, and/or as modulators of splicing. 1194-. (canceled)196. The compound of having at least two tetrahydropyran regions.197. The compound of having at least three tetrahydropyran regions.198. The compound of having a motif:{'br': None, 'sub': 1', '1', 'n1', '2', 'n2', '3', 'n3', '4', 'n4', '5', 'n5', '2, 'T-(Nu)-(Nu)-(Nu)-(Nu)-(Nu)-T, wherein{'sub': 1', '3', '5, 'Nu, Nu, and Nuare each independently tetrahydropyran nucleoside analogs of Formula I;'}{'sub': 2', '4, 'Nuand Nuare each independently modified or unmodified nucleosides or nucleoside analogs other than tetrahydropyran nucleoside analogs;'}each of n1 and n5 is, independently from 0 to 3;the sum of n2 plus n4 is between 10 and 25;n3 is from 0 and 5; and{'sub': 1', '2, 'each Tand Tis, independently, H, a hydroxyl protecting group, an optionally linked conjugate group or a capping group.'}199. The compound of claim 195 , wherein one of Rand Ris H and the other of Rand Ris H claim 195 , OCHor F for at least one tetrahydropyran nucleoside analog.200. The compound of wherein at least one internucleoside linking group is a phosphodiester internucleoside linking group.201. The compound of wherein at least one internucleoside linking group is a phosphorothioate internucleoside linking group.202. The compound of wherein each internucleoside linking group is a phosphorothioate internucleoside linking group.204. The compound of wherein the target non-coding RNA is a target pri-microRNA claim 203 , a target pre-microRNA claim 203 , or a target microRNA.205. The compound of comprising at least two tetrahydropyran nucleosides of Formula I.206. The compound of wherein each monomer of the oligomeric compound is a tetrahydropyran nucleoside of Formula I.207. The compound of ...

Подробнее
26-01-2012 дата публикации

TETRAHYDROPYRAN NUCLEIC ACID ANALOGS

Номер: US20120022014A1
Принадлежит:

The present disclosure describes tetrahydropyran nucleoside analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, novel tetrahydropyran nucleoside analogs are provided having at least one chiral substituent that are expected to be useful for enhancing one or more properties of oligomeric compounds such as nuclease resistance and/or binding affinity. In certain embodiments, the oligomeric compounds are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. 2. The tetrahydropyran nucleoside analog of wherein g claim 1 , g claim 1 , g claim 1 , g claim 1 , g claim 1 , and gare each H.3. The tetrahydropyran nucleoside analog of wherein at least one of g claim 1 , g claim 1 , g claim 1 , g claim 1 , g claim 1 , and gis other than H.4. The tetrahydropyran nucleoside analog of wherein at least one of g claim 1 , g claim 1 , g claim 1 , g claim 1 , g claim 1 , and gis methyl.5. The tetrahydropyran nucleoside analog of any one of to wherein qand qare each H.6. The tetrahydropyran nucleoside analog of any one of to wherein at least one of qand qis other than H.7. The tetrahydropyran nucleoside analog of any one of to wherein at least one of qand qis methyl.8. The tetrahydropyran nucleoside analog of any one of to wherein qis methyl and qis H or qis methyl and qis H.9. The tetrahydropyran nucleoside analog of any one of to wherein Bx is uracil claim 1 , 5-methyluracil claim 1 , 5-thiazolo-uracil claim 1 , 2-thio-uracil claim 1 , 5-propynyl-uracil claim 1 , thymine claim 1 , 2′-thio-thymine claim 1 , cytosine claim 1 , 5-methylcytosine claim 1 , 5-thiazolo-cytosine claim 1 , 5-propynyl-cytosine claim 1 , adenine claim 1 , guanine claim 1 , 2 claim 1 ,6-diaminopurine claim 1 , 1H-pyrimido[5 claim 1 ,4-b][1 claim 1 ,4-benzoxazin-2(3H)-one) claim 1 , 1H-pyrimido[5 claim 1 ,4-b][1 claim 1 ,4]benzothiazin-2(3H)-one claim 1 , 9-(2-aminoethoxy)-H-pyrimido[5 claim 1 ,4-b][1 ...

Подробнее
08-03-2012 дата публикации

Methods of using oligomeric compounds comprising 2'-substituted nucleosides

Номер: US20120059045A1
Принадлежит: ISIS PHARMACEUTICALS INC

The present disclosure provides oligomeric compounds comprising at least one 2′-fluoroethoxy modified nucleoside of formula I and methods of using these oligomeric compounds. The methods provided herein include contacting a cell or administering to an animal at least one of the oligomeric compounds. In certain embodiments, the oligomeric compounds hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.

Подробнее
22-03-2012 дата публикации

TETRAHYDROPYRAN NUCLEIC ACID ANALOGS

Номер: US20120071645A1
Принадлежит: Isis Pharmaceuticals, Inc.

The present disclosure describes tetrahydropyran nucleoside analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, tetrahydropyran nucleoside analogs are provided, having one or more chiral substituents, that are useful for enhancing properties of oligomeric compounds including nuclease resistance and binding affinity. In some embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. 2. The oligomeric compound of wherein essentially each internucleoside linking group is a phosphorothioate internucleoside linking group.3. The oligomeric compound of wherein essentially each internucleoside linking group is a phosphodiester internucleoside linking group.4. The oligomeric compound of wherein each internucleoside linking group is independently a phosphodiester or phosphorothioate internucleoside linking group.5. The oligomeric compound of comprising at least a first region of from 1 to about 5 contiguous tetrahydropyran nucleoside analogs of said formula.6. The oligomeric compound of comprising a second region of from 1 to about 5 contiguous tetrahydropyran nucleoside analogs of said formula separated from said first region by a third region comprising from about 6 to about 14 monomer subunits wherein each monomer subunit in the third region is claim 5 , independently claim 5 , a nucleoside or a modified nucleoside.7. The oligomeric compound of wherein each monomer subunit in the third region is a β-D-2′-deoxyribonucleoside.8. The oligomeric compound of wherein at least one β-D-2′-deoxyribonucleoside is linked to a tetrahydropyran nucleoside analog by a phosphorothioate internucleoside linking group.9. The oligomeric compound of wherein the third region comprises from 10 to 14 β-D-2′-deoxyribonucleosides.10. The oligomeric compound of wherein the first and third regions each have 2 contiguous tetrahydropyran nucleoside ...

Подробнее
10-05-2012 дата публикации

OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR THE USE IN MODULATION OF MICRORNAS

Номер: US20120115228A1
Принадлежит: Isis Pharmaceuticals, Inc.

Compounds, compositions and methods are provided for modulating the levels expression, processing and function of miRNAs. The compositions comprise oligomeric compounds targeted to small non-coding RNAs and miRNAs. The oligomeric compounds possess potent miRNA inhibitory activity, and further exhibit improved therapeutic index. Further provided are methods for selectively modulating miRNA activing in a cell. 1. An oligomeric compound comprising a contiguous sequence of about 17 to about 29 nucleosides linked by internucleoside linking groups , said sequence having an internal region located between two external regions , each external region independently comprises from 1 to about 3 nucleosides , each external region comprises a stabilizing modification , and the internal region comprises at least 10 β-D-2′-deoxy-2′-fluororibofuranosyl nucleosides.2. The oligomeric compound of wherein the contiguous sequence of linked nucleosides defines a gapped oligomeric compound comprising only β-D-2′-deoxy-2′-fluororibofuranosyl nucleosides in the internal region.3. The oligomeric compound of wherein the stabilizing modification comprises a stabilizing nucleoside claim 1 , a stabilizing internucleoside linkage group claim 1 , or a combination thereof.4. The oligomeric compound of wherein each stabilizing nucleoside provides enhanced nuclease stability relative to a β-D-2′-deoxyribofuranosyl nucleoside.5. The oligomeric compound of wherein the contiguous sequence of linked nucleosides defines a positionally modified oligomeric compound comprising from 2 to 6 stabilizing nucleosides in the internal region.6. The oligomeric compound of wherein each nucleoside in the internal region is claim 1 , independently claim 1 , a stabilizing nucleoside or a β-D-2′-deoxy-2′-fluororibofuranosyl nucleoside wherein at least one β-D-2′-deoxy-2′-fluororibofuranosyl nucleoside separates each stabilizing nucleoside in the internal region from each external region.7. The oligomeric compound of ...

Подробнее
21-06-2012 дата публикации

OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS

Номер: US20120157514A1
Принадлежит: REGULUS THERAPEUTICS INC.

Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided. 1. A method of treating or preventing a disease or disorder associated with a microRNA comprising:contacting an animal having or predisposed to the disease or disorder with a therapeutically effective amount of compound comprising an oligomeric compound consisting of 15 to 30 monomeric subunits;wherein the oligomeric compound is at least 90% complementary to the microRNA, and at least one monomeric subunit is a modified nucleoside;thereby treating or preventing the disease or disorder;wherein the disease or disorder is selected from cancer, diabetic retinopathy, cardiovascular disease, rheumatoid arthritis, and psoriasis, and wherein the oligomeric compound inhibits or reduces angiogenesis.2. The method of wherein the microRNA is selected from miR-29a claim 1 , miR-30b claim 1 , miR-123/126 as claim 1 , miR-133b claim 1 , miR-183 claim 1 , miR-187 claim 1 , miR-192 claim 1 , miR-210 claim 1 , miR-217 claim 1 , miR-220 claim 1 , and miR-222.3. The method of claim 2 , wherein the oligomeric compound is at least 95% complementary to the microRNA.4. The method of claim 2 , wherein the oligomeric compound is 100% complementary to the microRNA.5. The method of claim 2 , wherein the oligomeric compound is 100% complementary to at least an 8-nucleobase portion of the microRNA.6. The method of claim 1 , wherein the oligomeric compound consists of an oligonucleotide.7. The method of claim 1 , wherein at least one monomeric subunit comprises a modified sugar moiety.8. The method of claim 7 , wherein the modified sugar moiety is selected from a 2′-F sugar moiety claim ...

Подробнее
05-07-2012 дата публикации

BICYCLIC CYCLOHEXOSE NUCLEIC ACID ANALOGS

Номер: US20120172414A1
Принадлежит: Isis Pharmaceuticals, Inc.

The present invention provides bicyclic cyclohexose nucleoside analogs and oligomeric compounds comprising these nucleoside analogs. These bicyclic nucleoside analogs are useful for enhancing properties of oligomeric compounds including nuclease resistance. 1105-. (canceled)107. The bicyclic nucleoside analog of wherein Bx is uracil claim 106 , thymine claim 106 , cytosine claim 106 , 5-methylcytosine claim 106 , adenine or guanine.108. The bicyclic nucleoside analog of wherein three of E claim 106 , E claim 106 , Eand Eare H.109. The bicyclic nucleoside analog of wherein Land Lare each H.110. The bicyclic nucleoside analog of wherein one of Land Lis H and the other of Land Lis CH.111. The bicyclic nucleoside analog of wherein Tis 4 claim 106 ,4′-dimethoxytrityl and Tis diisopropylcyanoethoxy phosphoramidite.112. The bicyclic nucleoside analog of wherein Q is 5′-CRR—O-2′ or 5′-(CRR)-2′.113. The bicyclic nucleoside analog of wherein each Rand Ris H.114. The bicyclic nucleoside analog of wherein Q is 5′-CH—O-2′.115. The bicyclic nucleoside analog of wherein said reactive phosphorus group is diisopropylcyanoethoxy phosphoramidite or H-phosphonate.119. The oligomeric compound of wherein independently for each bicyclic nucleoside analog of formula II claim 118 , Bx is uracil claim 118 , thymine claim 118 , cytosine claim 118 , 5-methylcytosine claim 118 , adenine or guanine.120. The oligomeric compound of wherein independently for each bicyclic nucleoside analog of formula II claim 118 , three of E claim 118 , E claim 118 , Eand Eare H.121. The oligomeric compound of wherein independently for each bicyclic nucleoside analog of formula II claim 118 , Land Lare each H.122. The oligomeric compound of wherein independently for each bicyclic nucleoside analog of formula II claim 118 , one of Land Lis H and the other of Land Lis CH.123. The oligomeric compound of wherein each Q is 5′-CRR—O-2′ or 5′-(CRR)-2′.124. The oligomeric compound of wherein each Rand Ris H.125. The ...

Подробнее
19-07-2012 дата публикации

ANTISENSE INHIBITION VIA RNASE H-INDEPENDENT REDUCTION IN MRNA

Номер: US20120184031A1
Принадлежит: Isis Pharmaceuticals, Inc.

The present invention provides compositions and methods for reducing levels of a preselected mRNA, using antisense compounds targeted to a splice site or a region up to 50 nucleobases upstream of an exon/intron junction on said mRNA. Preferably, said antisense compounds do not elicit RNAse H cleavage of the mRNA. 126-. (canceled)27. A method of decreasing the amount of a preselected human cellular mRNA or corresponding protein in a cell comprising:contacting the cell expressing the preselected cellular mRNA with an oligomeric compound comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides having a nucleobase sequence that is specifically hybridizable to a target region of the preselected mRNA selected from the group consisting of an intron/exon junction, an exon/intron junction and a region 1 to 50 nucleobases 5′ of an exon/intron junction,wherein each nucleoside of the modified oligonucleotide comprises a modified sugar moiety comprising a modification at the 2′-position,wherein said oligomeric compound is not a substrate for RNAse H when bound to said preselected mRNA, andwherein the amount of the preselected mRNA or corresponding protein is reduced.28. The method of claim 27 , wherein the target region is selected from the group consisting of a region 1 to 15 nucleobases 5′ of an exon/intron junction claim 27 , 20 to 24 nucleobases 5′ of an exon/intron junction claim 27 , and 30 to 50 nucleobases 5′ of an exon/intron junction.29. The method of claim 27 , wherein said 2′ sugar modification is a substituted or unsubstituted 2′-O-alkyl claim 27 , substituted or unsubstituted 2′-O-alkyl-O-alkyl claim 27 , 2′-acetamido claim 27 , 2′-guanidinium claim 27 , 2′-carbamate claim 27 , 2′-fluoro or 2′-aminooxy modification.30. The method of claim 29 , wherein said substituted or unsubstituted 2′-O-alkyl modification is a 2′-O-methyl modification.31. The method of claim 29 , wherein said substituted or unsubstituted 2′-O-alkyl-O-alkyl modification is ...

Подробнее
16-08-2012 дата публикации

COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF GCGR

Номер: US20120208864A1
Принадлежит: Isis Pharmaceuticals, Inc.

The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing. 1. A method of treating a metabolic disorder in an animal , comprising administering to an animal a short antisense compound 10 to 14 monomers in length , said compound comprising a 2′-deoxyribonucleotide gap region flanked on each side by a wing , wherein each wing independently comprises 1 to 3 high-affinity modified monomers and wherein the compound is targeted to a nucleic acid encoding GCGR.2. The method of claim 1 , wherein administering the antisense compound increases insulin sensitivity claim 1 , decreases blood glucose and/or decreases HbAin the animal.3. The method of claim 1 , wherein the gap region is 5 claim 1 , 6 claim 1 , 7 claim 1 , 8 claim 1 , 9 claim 1 , or 10 nucleotides in length.4. The method of claim 1 , wherein said high-affinity modified monomers are sugar-modified nucleotides.5. The method of claim 4 , wherein at least one of the sugar-modified nucleotides comprises a bridge between the 4′ and the 2′ position of the sugar.6. The method of claim 4 , wherein each of said sugar-modified nucleotides comprises a 2′-substituent group that is other than H or OH.7. The method of claim 6 , wherein at least one of said sugar-modified nucleotides is a 4′ to 2′ bridged bicyclic nucleotide.8. The method of ...

Подробнее
18-10-2012 дата публикации

Oligomeric compounds and excipients

Номер: US20120264806A1
Принадлежит: ISIS PHARMACEUTICALS INC

The present invention provides method of optimizing the efficacy and potency of antisense compounds. In certain embodiments, the invention provides assays useful for determining favorable oligonucleotide characteristics and excipients for improved cellular uptake.

Подробнее
01-11-2012 дата публикации

Modulation of signal transducer and activator of transcription 3 (stat3)expression

Номер: US20120277284A1
Принадлежит: ISIS PHARMACEUTICALS INC

Disclosed herein are antisense compounds and methods for decreasing STAT3 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate hyperproliferative diseases.

Подробнее
08-11-2012 дата публикации

MODULATION OF EIF4E EXPRESSION

Номер: US20120283312A1
Принадлежит: Isis Pharmaceuticals, Inc.

Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided. 1. An antisense oligonucleotide consisting of 12 to 30 linked nucleosides and having a nucleobase sequence comprising at least 12 contiguous nucleobases of SEQ ID NO: 40 , or a pharmaceutically acceptable salt thereof , wherein the antisense oligonucleotide or pharmaceutically acceptable salt thereof comprises at least one chemically modified sugar moiety , internucleoside linkage , or nucleobase.2. The antisense oligonucleotide or pharmaceutically acceptable salt thereof of claim 1 , wherein the chemically modified sugar moiety is a 2′-O-(2-methoxyethyl) sugar moiety.3. The antisense oligonucleotide or pharmaceutically acceptable salt thereof of claim 1 , wherein the modified internucleoside linkage is a phosphorothioate internucleoside linkage.4. The antisense oligonucleotide or pharmaceutically acceptable salt thereof of claim 1 , wherein the modified nucleobase is a 5-methylcytosine.5. The antisense oligonucleotide or pharmaceutically acceptable salt thereof of ; wherein every internucleoside linkage is a phosphorothioate linkage claim 1 , nucleotides 1-5 and 16-20 reading from the 5′ end to the 3′ end of SEQ ID NO: 40 each comprise a 2′-O-(methoxyethyl) sugar claim 1 , nucleotides 6-15 are 2′-deoxynucleotides claim 1 , and every cytosine residue is a 5-methylcytosine.6. The antisense oligonucleotide or pharmaceutically acceptable salt thereof of which is in the form of a sodium salt.7. The antisense oligonucleotide or pharmaceutically acceptable salt thereof of claim 1 , wherein the antisense oligonucleotide or pharmaceutically acceptable salt thereof is single stranded.8. A ...

Подробнее
22-11-2012 дата публикации

MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION

Номер: US20120295961A1
Принадлежит:

Disclosed herein are antisense compounds and methods for decreasing HBV mRNA, DNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate HBV-related diseases, disorders or conditions. 1. A compound comprising a modified oligonucleotide consisting of 10 to 30 linked nucleosides and having a nucleobase sequence comprising at least 8 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 18-35 , wherein said modified oligonucleotide is chimeric and wherein said modified oligonucleotide is at least 95% complementary to SEQ ID NO: 1.2. The compound of claim 1 , wherein said modified oligonucleotide is at least 99% complementary to SEQ ID NO: 1.3. The compound of claim 1 , wherein said modified oligonucleotide is 100% complementary to SEQ ID NO: 1.4. The compound of claim 1 , consisting of a single-stranded modified oligonucleotide.5. The compound of claim 1 , wherein at least one internucleoside linkage is a modified internucleoside linkage.6. The compound of claim 5 , wherein each internucleoside linkage is a phosphorothioate internucleoside linkage.7. The compound of claim 1 , wherein at least one nucleoside of the modified oligonucleotide comprises a modified sugar.8. The compound of claim 7 , wherein the at least one modified sugar is a bicyclic sugar.9. (canceled)10. The compound of claim 8 , wherein the bicyclic sugar comprises a 4′-CH—O-2′ group.11. The compound of claim 1 , wherein at least one nucleoside comprises a modified nucleobase.12. The compound of claim 11 , wherein the modified nucleobase is a 5-methylcytosine.13. The compound of claim 1 , wherein the modified oligonucleotide comprises:a gap segment consisting of linked deoxynucleosides;a 5′ wing segment consisting of linked nucleosides; anda 3′ wing segment consisting of linked nucleosides;wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment ...

Подробнее
03-01-2013 дата публикации

ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS

Номер: US20130005674A1
Принадлежит: Isis Pharmaceuticals, Inc.

The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection. 136-. (canceled)38. A pharmaceutical composition according to claim 37 , wherein mm is 1.39. A pharmaceutical composition according to claim 37 , wherein mm is 2.40. A pharmaceutical composition according to claim 37 , wherein each Ris H.41. A pharmaceutical composition according to claim 37 , wherein Zis —OH.42. A pharmaceutical composition according to claim 37 , wherein Ris H.43. A pharmaceutical composition according to claim 42 , wherein Ris substituted C-Calkyl.44. A pharmaceutical composition according to claim 38 , wherein:{'sub': '10', 'Ris H;'}{'sub': 11', '1', '12, 'Ris substituted C-Calkyl;'}{'sub': '2', 'each Ris H; and'}{'sub': '1', 'Zis —OH.'}45. A pharmaceutical composition according to claim 45 , wherein mm is 1.46. A pharmaceutical composition according to claim 45 , wherein mm is 2.48. A pharmaceutical composition according to claim 47 , wherein mm is 1.49. A pharmaceutical composition according to claim 47 , wherein mm is 2.50. A pharmaceutical composition according to claim 47 , wherein each Ris H.51. A pharmaceutical composition according to claim 47 , wherein Zis —OH.52. A pharmaceutical composition according to claim 47 , wherein Ris H.53. A pharmaceutical composition according to claim 52 , wherein Ris substituted C-Calkyl.54. A pharmaceutical composition according to claim 47 , wherein:{'sub': '10', 'Ris H;'}{'sub': 11', '1', '12, 'Ris substituted C-Calkyl;'}{'sub': '2', 'each Ris H; and'}{'sub': '1', 'Zis —OH.'}55. A pharmaceutical composition according to claim 54 , wherein mm is 1.56. A pharmaceutical composition according to claim 54 , wherein mm is 2.58. A pharmaceutical composition according to claim 57 , wherein one of Zand Zis H.59. A pharmaceutical composition according to claim 57 , wherein:{'sub': 1', '12', '1', '12', '2', '12', '2', '12', '2', '12', '2', '12', ...

Подробнее
07-02-2013 дата публикации

MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION

Номер: US20130035366A1
Принадлежит:

Disclosed herein are antisense compounds and methods for decreasing HBV mRNA, DNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate HBV-related diseases, disorders or conditions. 1. A compound , comprising a single-stranded modified oligonucleotide consisting of 10 to 30 linked nucleosides and having a nucleobase sequence comprising any of the nucleobase sequences of SEQ ID NOs: 17 , 50 , 224 , 226 , 722 , 807 , 1327 , 1340 , and 1379 , wherein the modified oligonucleotide is at least 96% complementary over its entire length with a nucleic acid encoding hepatitis B virus (HBV) and at least one nucleoside of the modified oligonucleotide comprises a modified sugar.2. (canceled)3. (canceled)4. The compound of claim 1 , wherein said modified oligonucleotide is at least 98% complementary to SEQ ID NO: 1.5. (canceled)6. The compound of claim 1 , wherein said modified oligonucleotide is 100% complementary to SEQ ID NO: 1.7. (canceled)8. The compound of claim 1 , wherein the modified oligonucleotide comprises at least one modified internucleoside linkage.9. The compound of claim 8 , wherein each internucleoside linkage is a phosphorothioate internucleoside linkage.10. (canceled)11. The compound of claim 1 , wherein the at least one modified sugar is a bicyclic sugar.12. The compound of claim 1 , wherein the at least one modified sugar comprises a 2′-O-methoxyethyl group.13. (canceled)14. The compound of claim 1 , wherein the at least one modified sugar comprises a 4′-CH(CH)—O-2′ group.15. The compound of claim 1 , wherein at least one nucleoside comprises a modified nucleobase.16. The compound of claim 15 , wherein the modified nucleobase is a 5-methylcytosine.17. The compound of claim 1 , wherein the modified oligonucleotide comprises:a gap segment consisting of linked deoxynucleosides;a 5′ wing segment consisting of linked nucleosides; anda 3′ wing segment consisting of linked nucleosides;wherein the gap segment ...

Подробнее
07-02-2013 дата публикации

DOUBLE STRAND COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENE MODULATION

Номер: US20130035369A1
Принадлежит: Isis Pharmaceuticals, Inc.

The present invention provides double stranded compositions wherein the first strand is modified to have a particular motif and the second strand is modified a selected motif. More particularly, the present compositions comprise an antisense strand that is modified to have a positional/full motif and the sense strand is modified to have an alternating motif, a hemimer motif, a blockmer motif, a gapped motif, a positional motif, a positional/full motif or a fully modified motif. Each strand further comprises one or more phosphorothioate internucleoside linkage. The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes. 154.-. (canceled)55. A composition comprising first and second chemically synthesized oligomeric compounds , wherein:the first oligomeric compound comprises a hybridizing region that is essentially fully complementary to a nucleic acid target and comprises an alternating motif;{'sub': '3', 'wherein the alternating motif has 2′-modified nucleosides that alternate between 2′-F and 2′-O—CH;'}wherein the second oligomeric compound comprises a hybridizing region that is essentially fully complementary to the hybridizing region of the first oligomeric compound and comprises a continuous sequence of nucleosides that define a motif selected from an alternating motif, a hemimer motif, a blockmer motif, a gapped motif, a positional motif, a positional/full motif or a fully modified motif; andeach of the first and second oligomeric compounds can comprise one or more optional groups independently selected from a 3′-capping group, a 5′-capping group, a 5′-phosphate moiety, a 3′-linked conjugate group, a non hybridizing 3′-overhang region and a non hybridizing 3′-overhang region that is linked to a conjugate group.56. The composition of wherein the hybridizing regions of the first and second oligomeric compounds are fully complementary to each other.57. The composition of any one of wherein the ...

Подробнее
14-02-2013 дата публикации

BASE MODIFIED BICYCLIC NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM

Номер: US20130041011A1
Принадлежит: Isis Pharmaceuticals, Inc.

Provided herein are novel base modified bicyclic nucleosides, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, novel pyrimidine bicyclic nucleosides are provided wherein each pyrimidine base is substituted at the 5 position with an optionally substituted, aromatic or heteroaromatic ring system comprising from 5 to 7 ring atoms selected from C, N, O and S. In certain embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. 2. The bicyclic nucleoside of wherein qand qare each claim 1 , independently claim 1 , H claim 1 , halogen claim 1 , C-Calkyl or substituted C-Calkyl.3. The bicyclic nucleoside of wherein qand qare each H.4. The bicyclic nucleoside of wherein Zis NHor NHPg and Ztogether with Zcomprise a bond.5. The bicyclic nucleoside of wherein Zand Ztogether are ═Xand Zis H.6. The bicyclic nucleoside of wherein Xis O.7. The bicyclic nucleoside of wherein G is —(C(RR))— claim 1 , —(C(RR))—O— claim 1 , —(C(RR))—S— claim 1 , —(C(RR))—(NR)— claim 1 , —C(═O)—N(R)—C(RR)— claim 1 , —C(RR)—N(R)—C(RR)— claim 1 , —C(RR)—O—N(R)— claim 1 , —C(RR)—N(R)—O— or —C(RR)—C(═C(RR))— wherein n is from 1 to 3 and wherein G forms a 5 or 6 membered ring with the furanose ring of the nucleoside.8. The bicyclic nucleoside of wherein G is 4′-(CH)—O-2′ claim 1 , 4′-(CH)—O-2′ claim 1 , 4′-CH(CH)—O-2′ claim 1 , 4′-C(CH)—O-2′ claim 1 , 4′-CH(CHOCH)—O-2′ claim 1 , 4′-C(═O)—N(CH)—CH-2′ claim 1 , 4′-CH—N(CH)—CH-2′ claim 1 , 4′-CH—N(OCH)-2′ claim 1 , 4′-CH—N(O(CH)—OCH)-2′ claim 1 , 4′-CH—O—N(CH)-2′ claim 1 , 4′-CH—N(CH)—O-2′ claim 1 , 4′-CH—CH(CH)-2′ or 4′-CH—C(═CH)-2′.9. The bicyclic nucleoside of wherein G is 4′-(CH)—O-2′ claim 1 , 4′-CH(CH)—O-2′ claim 1 , 4′-C(CH)—O-2′ claim 1 , 4′-CH—N(OCH)-2′ claim 1 , 4′-CH—N(O(CH)—OCH)-2′ claim 1 , 4′-CH—O—N(CH)-2′ claim 1 , 4′-CH—N(CH)—O-2′ claim 1 , 4′-CH—CH(CH)-2′ or 4′-CH—C(═CH)-2′.10. The bicyclic ...

Подробнее
14-02-2013 дата публикации

5'-SUBSTITUTED BICYCLIC NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM

Номер: US20130041144A1
Принадлежит: Isis Pharmaceuticals, Inc.

Provided herein are novel 5′-(S)—CHsubstituted bicyclic nucleosides, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, the furanose ring of each of the novel 5′-(S)—CHsubstituted bicyclic nucleosides includes a 2′ to 4′ bridging group. The 5′-(S)—CHsubstituted bicyclic nucleosides are expected to be useful for enhancing one or more properties of the oligomeric compounds they are incorporated into such as for example increasing the binding affinity. In certain embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. 2. The bicyclic nucleoside of wherein:{'sub': 1', '2', 'n', '1', '2', '1', '2', '3', '4', '1', '2', '3', '4', '1', '2', '3', '4, 'G is —[C(RR)]—, —C(R)═C(R)—, —C(R)═C(R)—C(RR)—, —C[═C(RR)]-C(RR)— or —C(RR)—C[═C(RR)]—;'}{'sub': 1', '2', '3', '4', '1', '6', '1', '6', '2', '6', '2', '6', '2', '6', '2', '6', '1, 'R, R, Rand Rare each independently, H, F, C-Calkyl, substituted C-Calkyl, C-Calkenyl, substituted C-Calkenyl, C-Calkynyl, substituted C-Calkynyl, CN or OJ;'}{'sub': '1', 'each substituted group comprises one or more optionally protected substituent groups independently selected from halogen and OJ; and'}{'sub': 1', '1', '6, 'Jis H or C-Calkyl.'}3. The bicyclic nucleoside of wherein:{'sub': 2', '2', '2', '3', '2', '3', '2', '3', '2', '2', '2', '2', '3', '3', '2', '3', '2', '2', '3', '2, 'G is —C(H)(CN)—, —(CH)—, —CH—C(H)(CH)—, —CH—C(H)[(R)—CH]—, —CH—C(H)[(S)—CH]—, —CH—C(═CH)—, —C(═CH)—CH—, —C(H)═C(H)—, —C(CH)═C(H)—, —C(H)═C(CH)—, —(CH)—, —(CH)—C*(H)(CH)— or —CH═CH—CH—.'}4. The bicyclic nucleoside of wherein:{'sub': 7', '1', '2', '1', '2', '7', '3', '4', '1', '2', '7', '1', '2', '7', '1', '2', '3', '1', '2', '3', '4', '7', '1', '2', '3', '4', '1', '2', '3', '4', '1', '2', '3', '4', '1', '2', '3', '4', '5', '6, 'G is —C(═O)—N(R)—C(RR)—, —C(RR)—N(R)—C(RR)—, —C(RR)—N(R)—O—, —C(RR)—O—N(R)—, —C(RR)—N(OR)—, —C(RR ...

Подробнее
21-02-2013 дата публикации

SELECTIVE REDUCTION OF ALLELIC VARIANTS

Номер: US20130046007A1
Принадлежит: Isis Pharmaceuticals Inc.

Disclosed herein are antisense compounds and methods for selectively of reducing expression of an allelic variant of a gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate diseases, including neurodegenerative, such as Huntington's Disease (HD). 1102.-. (canceled)103. A compound comprising a modified antisense oligonucleotide consisting of 12 to 30 linked nucleosides targeted to a single nucleotide polymorphism site , wherein the modified oligonucleotide comprises a wing-gap-wing motif with a 5′ wing region positioned at the 5′ end of a deoxynucleoside gap , and a 3′ wing region positioned at the 3′ end of the deoxynucleoside gap , wherein position 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , or 15 of the modified oligonucleotide , as counted from the 5′ terminus of the modified oligonucleotide , or positions 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , or 9 of the modified oligonucleotide , as counted from the 5′ terminus of the gap , aligns with the single nucleotide polymorphism.104. The compound of claim 103 , wherein the single nucleotide polymorphism site is on a mutant allele that is associated with a disease.105. The compound of claim 104 , wherein the disease is Huntington's Disease.106. The compound of claim 103 , wherein the single nucleotide polymorphism site contains a differentiating polymorphism.107. The compound of claim 103 , wherein the modified antisense oligonucleotide consists of 15 to 20 linked nucleosides.108. The compound of claim 103 , wherein position 8 claim 103 , 9 claim 103 , or 10 of the modified oligonucleotide claim 103 , as counted from the 5′ terminus of the modified oligonucleotide claim 103 , or positions 4 claim 103 , 5 claim 103 , or 6 of the modified oligonucleotide claim 103 , as counted from the 5′ terminus of the gap claim 103 , aligns with the single nucleotide polymorphism.109. The compound of claim 103 , wherein the gap region is 7-11 nucleosides ...

Подробнее
21-02-2013 дата публикации

SELECTIVE REDUCTION OF ALLELIC VARIANTS

Номер: US20130046008A1
Принадлежит: Isis Pharmaceuticals, Inc.

Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a huntingtin gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate Huntington's Disease (HD). 197.-. (canceled)98. A method of selectively reducing the expression of a mutant huntingtin allele in a cell , tissue , or animal comprising administering to the cell , tissue , or animal a compound comprising a modified oligonucleotide complementary to the mutant huntingtin allele at a position comprising a single nucleotide polymorphism , wherein the expression of the mutant huntingtin allele is selectively reduced.99. The method of claim 98 , wherein the modified oligonucleotide consists of 15 to 20 linked nucleosides and position 5 claim 98 , 6 claim 98 , 7 claim 98 , 8 claim 98 , 9 claim 98 , 10 claim 98 , 11 claim 98 , 12 claim 98 , 13 claim 98 , 14 claim 98 , or 15 of the modified oligonucleotide claim 98 , as counted from the 5′ terminus of the modified oligonucleotide claim 98 , aligns with the single nucleotide polymorphism.100. The method of claim 99 , wherein at least one nucleoside comprises a modified sugar.101. The method of claim 100 , wherein the modified sugar is a high-affinity sugar modification.102. The method of claim 101 , wherein the high-affinity sugar is a bicyclic sugar.103. The method of claim 102 , wherein each bicyclic sugar comprises a 4′-CH(CH)—O-2′ bridge.104. The method of claim 101 , wherein the at least one modified sugar comprises a 2′-O-methoxyethyl.105. The method of claim 99 , wherein the modified oligonucleotide comprises a wing-gap-wing motif.106. The method of claim 105 , wherein the wing-gap-wing motif is any of the group consisting of 2-9-6 claim 105 , 3-9-3 claim 105 , 3-9-4 claim 105 , 3-9-5 claim 105 , 4-7-4 claim 105 , 4-9-4 claim 105 , 4-9-5 claim 105 , 4-10-5 claim 105 , 4-11-4 claim 105 , 4-11-5 claim 105 , 5-7-5 claim 105 , ...

Подробнее
07-03-2013 дата публикации

METHODS AND COMPOSITIONS USEFUL IN TREATMENT OF DISEASES OR CONDITIONS RELATED TO REPEAT EXPANSION

Номер: US20130059902A1
Принадлежит: Isis Pharmaceuticals, Inc.

The present invention is drawn to chemically-modified oligomers that are complementary to, and capable of hybridizing within the repeat region of CAG, CUG, or CCUG nucleotide repeat-containing RNAs (NRRs). 170.-. (canceled)72. The chemically-modified oligonucleotide of claim 71 , wherein the nuclease-resistant modification is a modified sugar moiety or a modified internucleoside linkage.73. The chemically-modified oligonucleotide of claim 72 , wherein the modified sugar moiety is a bicyclic sugar moiety.74. The chemically-modified oligonucleotide of claim 73 , wherein the bicyclic sugar moiety is a 4′ to 2′ bicyclic sugar moiety.75. The chemically-modified oligonucleotide of claim 74 , wherein the bicyclic sugar moiety is a 4′-CH—O-2′ or 4′-CH(CH)—O-2′ bicyclic sugar moiety.76. The chemically-modified oligonucleotide of claim 71 , wherein each high-affinity sugar modification is a 2′-modified sugar moiety or a bicyclic sugar moiety.77. The chemically-modified oligonucleotide of claim 71 , wherein each T is independently a thymidine or uridine nucleoside comprising a 4′ to 2′ bicyclic sugar moiety.79. The chemically modified oligonucleotide of claim 78 , wherein each 4′ to 2′ bridge is independently —[C(R)(R)]— claim 78 , —[C(R)(R)]—O— claim 78 , —C(RR)—N(R)—O— or —C(RR)—O—N(R)— claim 78 , wherein:{'sub': c', 'd', '1', '6, 'each Rand Ris independently hydrogen, halogen, substituted or unsubstituted C-Calkyl; and'}{'sub': e', '1', '6, 'each Ris independently hydrogen or substituted or unsubstituted C-Calkyl.'}80. The chemically modified oligonucleotide of claim 79 , wherein for each 4′ to 2′ bridge is independently a 4′-(CH)′-(CH)′-CH—O-2′ claim 79 ,4′-CH(CH)—O-2′ claim 79 ,4′-(CH)-0-2′ claim 79 ,4′-CH—O—N(R)-2′ and 4′-CH—N(R)—O-2′-bridge.81. The chemically-modified oligonucleotide of claim 71 , wherein each T is a thymidine nucleoside comprising a 4′-CH(CH)—O-2′ bicyclic sugar moiety.82. The chemically-modified oligonucleotide of claim 71 , wherein the CAG nucleotide ...

Подробнее
04-04-2013 дата публикации

MODIFIED NUCLEOSIDES, ANALOGS THEREOF AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM

Номер: US20130084576A1
Принадлежит: Isis Pharmaceuticals, Inc.

The present invention provides modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom. More particularly, the present invention provides modified nucleosides and analogs thereof that are useful for incorporation at the terminus of an oligomeric compound. Such oligomeric compounds can also be included in a double stranded composition. In some embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. 158.-. (canceled)60. The compound of wherein Mis O.61. The compound of wherein J claim 60 , J claim 60 , Jand Jare each H.62. The compound of wherein Jforms a bridge with one of Jor J.64. The compound of wherein Qand Qare each H.66. The compound of wherein G is halogen claim 65 , OCH claim 65 , OCHF claim 65 , OCHF claim 65 , OCF claim 65 , OCHCH claim 65 , O(CH)F claim 65 , OCHCHF claim 65 , OCHCF claim 65 , OCH—CH═CH claim 65 , O(CH)—OCH claim 65 , O(CH)—SCH claim 65 , O(CH)—OCF claim 65 , O(CH)—N(R)(R) claim 65 , O(CH)—ONO(R)(R) claim 65 , O(CH)—O(CH)—N(R)(R) claim 65 , OCHC(═O)—N(R)(R) claim 65 , OCHC(═O)—N(R)—(CH)—NR)(R) or O(CH)—N(R)—C(═NR)[N(R)(R)] wherein R claim 65 , R claim 65 , Rand Rare each claim 65 , independently claim 65 , H or C-Calkyl.67. The compound of wherein said heterocyclic base moiety is a pyrimidine claim 66 , substituted pyrimidine claim 66 , purine or substituted purine.68. The compound of wherein said heterocyclic base moiety is uracil claim 67 , thymine claim 67 , cytosine claim 67 , 5-methylcytosine claim 67 , adenine or guanine.70. The oligomeric compound of wherein Mis O.71. The oligomeric compound of wherein J claim 70 , J claim 70 , Jand Jare each H.72. The oligomeric compound of wherein Jforms a bridge with one of Jor J.74. The oligomeric compound of wherein Qand Qare each H.76. The oligomeric compound of wherein Ris O and Rand Rare each claim 75 , independently claim 75 , OCH claim 75 , OCHCHor OCH(CH). ...

Подробнее
02-05-2013 дата публикации

MODIFIED 5' DIPHOSPHATE NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM

Номер: US20130109850A1
Принадлежит: Isis Pharmaceuticals, Inc

Provided herein are modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom. More particularly, modified 5′ diphosphate nucleosides are provided that can be further modified at the 2′ and 5′ positions. In some embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. The oligomeric compounds are also expected to be useful as primers and probes in diagnostic applications. 150-. (canceled)52. The compound of wherein Bx is uracil claim 51 , thymine claim 51 , cytosine claim 51 , 5-methylcytosine claim 51 , adenine or guanine.53. The compound of any one of wherein r is 1 claims 52 , Mis H and Mis OH.54. The compound of any one of wherein r is 0 claims 53 , Mis O(CH)CN and Mis N[CH(CH)].55. The compound of wherein G is halogen claim 54 , OCH claim 54 , OCHF claim 54 , OCHF claim 54 , OCF claim 54 , OCHCH claim 54 , O(CH)F claim 54 , OCHCHF claim 54 , OCHCF claim 54 , OCH—CH═CH claim 54 , O(CH)—OCH claim 54 , O(CH)—SCH claim 54 , O(CH)—OCF claim 54 , O(CH)—N(R)(R) claim 54 , O(CH)—ON(R)(R) claim 54 , O(CH)—O(CH)—N(R)(R) claim 54 , OCHC(═O)—N(R)(R) claim 54 , OCHC(═O)—N(R)—(CH)—N(R)(R) or O(CH)—N(R)—C(═NR)[N(R)(R)] wherein R claim 54 , R claim 54 , Rand Rare each claim 54 , independently claim 54 , H or C-Calkyl.56. The compound of wherein G is halogen claim 55 , OCH claim 55 , OCF claim 55 , OCHCH claim 55 , OCHCF claim 55 , OCH—CH═CH claim 55 , O(CH)—OCH claim 55 , O(CH)—O(CH)—N(CH) claim 55 , OCHC(═O)—N(H)CH claim 55 , OCHC(═O)—N(H)—(CH)—N(CH)or OCH—N(H)—C(═NH)NH.57. The compound of wherein G is F claim 56 , OCH claim 56 , O(CH)—OCH claim 56 , OCHC(═O)—N(H)CHor OCHC(═O)—N(H)—(CH)—N(CH).58. The compound of wherein G is O(CH)—OCH.59. The compound of wherein each Pg is claim 58 , independently claim 58 , methyl claim 58 , ethyl claim 58 , isopropyl claim 58 , tert-butyl claim 58 , 2-cyanoethyl claim 58 , benzyl claim 58 , phenyl claim 58 , 4- ...

Подробнее
09-05-2013 дата публикации

5' MODIFIED NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM

Номер: US20130116420A1
Принадлежит: Isis Pharmaceuticals, Inc.

The present invention provides 5′ modified nucleosides and oligomeric compounds prepared therefrom. More particularly, the present invention provides modified nucleosides having at least one 5′-substituent and an optional 2′ substituent, oligomeric compounds comprising at least one of these modified nucleosides and methods of using the oligomeric compounds. In some embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. 146-. (canceled)48. The 5′ modified nucleoside of wherein Bx is uracil claim 47 , thymine claim 47 , cytosine claim 47 , 5-methylcytosine claim 47 , adenine or guanine.49. The 5′ modified nucleoside of wherein qand qare each claim 48 , independently claim 48 , OCH claim 48 , OCHCHor OC(H)(CH)and qis O.50. The 5′ modified nucleoside of wherein r is 1 claim 49 , Mis H and Mis hydroxyl or r is 0 claim 49 , Mis O(CH)CN and Mis N[CH(CH)].51. The 5′ modified nucleoside of wherein G is halogen claim 50 , OCH claim 50 , OCHF claim 50 , OCHF claim 50 , OCF claim 50 , OCHCH claim 50 , O(CH)F claim 50 , OCHCHF claim 50 , OCHCF claim 50 , OCH—CH═CH claim 50 , O(CH)—OCH claim 50 , O(CH)—SCH claim 50 , O(CH)—OCF claim 50 , O(CH)—N(R)(R) claim 50 , O(CH)—ON(R)(R) claim 50 , O(CH)—O(CH)—N(R)(R) claim 50 , OCHC(═O)—N(R)(R) claim 50 , OCHC(═O)—N(R)—(CH)—N(R)(R) or O(CH)—N(R)—C(═NR)[N(R)(R)] wherein R claim 50 , R claim 50 , Rand Rare each claim 50 , independently claim 50 , H or C-Calkyl.52. The 5′ modified nucleoside of wherein G is F claim 51 , OCH claim 51 , O(CH)—OCH claim 51 , OCHC(═O)—N(H)CHor OCHC(═O)—N(H)—(CH)—N(CH).53. The 5′ modified nucleoside of wherein g is 1.54. The 5′ modified nucleoside of wherein three of q claim 53 , q claim 53 , qand qare each H.55. The 5′ modified nucleoside of wherein one of qand qis H claim 53 , one of qand qis H and the other two of q claim 53 , q claim 53 , qand qare other than H.56. The 5′ modified nucleoside of wherein ...

Подробнее
23-05-2013 дата публикации

SUBSTITUTED 2'-AMINO AND 2'-THIO-BICYCLIC NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM

Номер: US20130131147A1
Принадлежит: Isis Pharmaceuticals, Inc.

Provided herein are 2′-amino and 2′-thio bicyclic nucleosides and oligomenc compounds prepared therefrom. The novel bicyclic nucleosides provided herein are expected to be useful for enhancing one or more properties of the oligomeric compounds they are incorporated into such as nuclease resistance. 192-. (canceled)94. The bicyclic nucleoside of wherein Bx is an optionally protected uracil claim 93 , thymine claim 93 , cytosine claim 93 , 5-methylcytosine claim 93 , adenine or guanine.95. The bicyclic nucleoside of wherein Tis 4 claim 93 ,4′-dimethoxytrityl and Tis diisopropylcyanoethoxy phosphoramidite.96. The bicyclic nucleoside of wherein Qand Qare each H.97. The bicyclic nucleoside of wherein one of Qand Qis H and the other of Qand Qis C-Calkyl or substituted C-Calkyl.98. The bicyclic nucleoside of wherein one of Qand Qis CH.99. The bicyclic nucleoside of wherein Gand Gare each H.100. The bicyclic nucleoside of wherein one of Gand Gis H and the other of Gand Gis C-Calkyl or substituted C-Calky.101. The bicyclic nucleoside of wherein at least one of Gand Gis CH.102. The bicycle nucleoside of wherein Z is NR wherein R is H claim 93 , C-Csubstituted C-Calkyl claim 93 , C-Calkoxy or substituted C-Calkoxy.103. The bicyclic nucleoside of wherein R is CHor methoxy.104. The bicyclic nucleoside of wherein Z is S.106. The bicyclic nucleoside of wherein three of Q claim 105 , Q claim 105 , Gand Gare H and the other one of Q claim 105 , Q claim 105 , Gand Gis CH.107. The bicyclic nucleoside of wherein two of Q claim 105 , Q claim 105 , Gand Gare H and the remaining two of Q claim 105 , Q claim 105 , Gand Gare CHwherein the two that are CHare selected from Qand G claim 105 , Qand G claim 105 , Qand G claim 105 , and Qand G.109. The oligomeric compound of wherein Bx is an optionally protected uracil claim 108 , thymine claim 108 , cytosine claim 108 , 5-methylcytosine claim 108 , adenine or guanine for each bicyclic nucleoside of Formula II.110. The oligomeric compound of ...

Подробнее
06-06-2013 дата публикации

ANTIBACTERIAL 4,6-SUBSTITUTED 6', 6'' AND 1 MODIFIED AMINOGLYCOSIDE ANALOGS

Номер: US20130144044A1
Принадлежит: Isis Pharmaceuticals, Inc.

The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection. 2. The compound of wherein said substituents are each claim 1 , independently claim 1 , OH claim 1 , NH claim 1 , N(H)C-Calkyl claim 1 , C(═O)—N(H)J claim 1 , N(H)C(═O)-J claim 1 , N(J)—(CH)—OJ claim 1 , N(J)—(CH)—NJJ claim 1 , C-Calicyclic radical claim 1 , C-Caryl claim 1 , a heterocycle radical or heteroaryl.3. The compound of wherein said substituents are each claim 1 , independently claim 1 , OH claim 1 , NH claim 1 , N(H)C-Calkyl or C-Caryl.4. The compound of wherein each Rand Ris H.5. The compound of wherein each Ris H.6. The compound of wherein Qis hydroxyl.7. The compound of wherein Qis NRR.8. The compound of wherein one of said Rand Ris H and the other of said Rand Ris C-Calkyl claim 7 , substituted C-Calkyl claim 7 , C-Calicyclic radical or substituted C-Calicyclic radical.9. The compound of wherein the other of said Rand Ris substituted C-Calkyl wherein each of said substituents is claim 8 , independently claim 8 , C-Caryl claim 8 , C-Calicyclic radical claim 8 , heterocycle radical or heteroaryl.10. The compound of wherein Qis NH.11. The compound of wherein Qis N(CHR)Rand Ris H or C-Calkyl.12. The compound of wherein Ris C-Calkyl claim 11 , substituted C-Calkyl claim 11 , C-Calicyclic radical or substituted C-Calicyclic radical.13. The compound of wherein Ris substituted C-Calkyl wherein said substituent is OH claim 11 , NH claim 11 , N(H)aC-Calkyl or C-Caryl.14. The compound of wherein said substituent is OH claim 13 , NHor N(H)C-Calkyl.15. The compound of wherein Ris substituted C-Calkyl wherein said substituent is C-Caryl.16. The compound of wherein one of Rand Ris H and the other of Rand Ris C-Calkyl or substituted C-Calkyl.17. The compound of wherein the other of Rand Ris substituted C-Calkyl wherein the substituent is a C-Calicyclic radical claim 16 , C-Caryl claim 16 , ...

Подробнее
13-06-2013 дата публикации

Bicyclic nucleosides and oligomeric compounds prepared therefrom

Номер: US20130150569A1
Принадлежит: ISIS PHARMACEUTICALS INC

The present invention provides novel 3′,5′-linked bicyclic nucleosides and oligomeric compounds prepared therefrom. The bicyclic nucleosides provided herein are useful for enhancing one or more properties of the oligomeric compounds they are incorporated into such as nuclease resistance.

Подробнее
20-06-2013 дата публикации

Lipid formulated single stranded rna

Номер: US20130156845A1

The present invention provides compositions comprising a nucleic acid lipid particle and an oligomeric compound and uses thereof. In certain embodiments, such compositions are useful as antisense compounds. Certain such antisense compounds are useful as RNase H antisense compounds or as RNAi compounds.

Подробнее
27-06-2013 дата публикации

COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF GCCR

Номер: US20130165496A1
Принадлежит: Isis Pharmaceuticals, Inc.

The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing. 1. A short antisense compound 8 to 14 monomers in length , comprising a 2′-deoxyribonucleotide gap region flanked on each side by a wing , wherein each wing independently comprises 1 to 3 high-affinity modified monomers and wherein the short antisense compound is targeted to a nucleic acid encoding diacylglycerol transferase 2 (DGAT2).2. The short antisense compound of claim 1 , wherein said high-affinity modified monomers are sugar-modified nucleotides.3. The short antisense compound of claim 2 , wherein at least one of the sugar-modified nucleotides comprises a bridge between the 4′ and the 2′ position of the sugar.4. The short antisense compound of claim 2 , wherein each of said high-affinity modified nucleotides confers a ΔTof 1 to 4 degrees per nucleotide.5. The short antisense compound of claim 2 , wherein each of said sugar-modified nucleotides comprises a 2′-substituent group that is other than H or OH.6. The short antisense compound of claim 5 , wherein at least one of said sugar-modified nucleotides is a 4′ to 2′ bridged bicyclic nucleotide.7. The short antisense compound of claim 5 , wherein each of the 2′-substituent groups is claim 5 , independently claim 5 , alkoxy claim 5 , substituted alkoxy claim 5 , or ...

Подробнее
11-07-2013 дата публикации

MODULATION OF EIF4E EXPRESSION

Номер: US20130178513A1
Принадлежит: Isis Pharmaceuticals, Inc.

Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided. 1. An antisense oligonucleotide consisting of 12 to 30 linked nucleosides and having a nucleobase sequence at least 95% complementary within the 3′ untranslated region (3′UTR) of a nucleic acid encoding human eIF4E , wherein the antisense oligonucleotide comprises at least one chemically modified sugar moiety , internucleoside linkage , or nucleobase.2. The antisense oligonucleotide of claim 1 , wherein the chemically modified sugar moiety is a 2′-O-(2-methoxyethyl) sugar moiety.3. The antisense oligonucleotide of claim 1 , wherein the chemically modified sugar moiety is a bicyclic sugar moiety.4. The antisense oligonucleotide of claim 3 , wherein the bicyclic sugar moiety comprises a 4′-(CH2)-O-2′ or 4′-(CH2)2-O-2′ group.5. The antisense oligonucleotide of claim 1 , wherein the modified internucleoside linkage is a phosphorothioate internucleoside linkage.6. The antisense oligonucleotide of claim 1 , wherein the modified nucleobase is a 5-methylcytosine.7. The antisense oligonucleotide of claim 1 , wherein the antisense oligonucleotide is chimeric.8. A pharmaceutical composition comprising the antisense oligonucleotide of claim 1 , and a pharmaceutically or physiologically acceptable carrier claim 1 , diluent claim 1 , or excipient.9. The pharmaceutical composition of claim 8 , which is in a form suitable for parenteral administration.10. The pharmaceutical composition of claim 9 , wherein said parenteral administration is via intravenous injection or infusion.11. The antisense oligonucleotide of claim 1 , wherein the antisense oligonucleotide has a nucleobase sequence at least 95% ...

Подробнее
01-08-2013 дата публикации

OLIGOMERIC COMPOUNDS COMPRISING TRICYCLIC NUCELOSIDES AND METHODS FOR THEIR USE

Номер: US20130197062A1
Принадлежит: Isis Pharmaceuticals, Inc.

The present disclosure provides tricyclic nucleosides, oligomeric compounds comprising at least one of the tricyclic nucleosides and methods of using the oligomeric compounds. The methods provided herein include contacting a cell or administering to an animal at least one of the oligomeric compounds. In certain embodiments, the oligomeric compounds hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. 2. The oligomeric compound of wherein qand qare H for each of said tricyclic nucleosides having formula II.3. The oligomeric compound of wherein at least one of q claim 1 , q claim 1 , qand qis other than H for each of said tricyclic nucleosides having formula II.4. The oligomeric compound of wherein at least one of q claim 1 , q claim 1 , qand qis fluoro for each of said tricyclic nucleosides having formula II.5. The oligomeric compound of wherein at least one of qand qis fluoro for each of said tricyclic nucleosides having formula II.6. The oligomeric compound of wherein at least one of qand qis fluoro for each of said tricyclic nucleosides having formula II.7. The oligomeric compound of wherein qand qare each fluoro for each of said tricyclic nucleosides having formula II.8. The oligomeric compound of wherein at least one of q claim 2 , q claim 2 , qand qis C-Calkyl for each of said tricyclic nucleosides having formula II.9. The oligomeric compound of wherein at least one of q claim 8 , q claim 8 , qand qis methyl for each of said tricyclic nucleosides having formula II.10. The oligomeric compound of wherein each q claim 1 , q claim 1 , qand qis H.11. The oligomeric compound of wherein zis fluoro for each of said tricyclic nucleosides having formula II.12. The oligomeric compound of wherein zis fluoro for each of said tricyclic nucleosides having formula II.13. The oligomeric compound of wherein zand zare each fluoro for each of said tricyclic nucleosides having formula II.14. The oligomeric compound of claim 1 , wherein at ...

Подробнее
08-08-2013 дата публикации

2' AND 5' MODIFIED MONOMERS AND OLIGONUCLEOTIDES

Номер: US20130203836A1
Принадлежит:

The present invention provides nucleosides of formula (1) and oligonucleotides comprising at least on nucleoside of formula (2):Formula (1) and Formula (2). Another aspect of the invention relates to a method of inhibiting the expression of a gene in call, the method comprising (a) contacting an oligonucleotide of the invention with the cell; and (b) maintaining the cell from step (a) for a time sufficient to obtain degradation of the mRNA of the target gene. 10. The oligonucleotide of claim 5 , wherein at least one of Tand Tis methyl.11. The oligonucleotide of claim 5 , wherein one of Tand Tis methyl and the other of T claim 5 , and Tis H.12. The oligonucleotide of wherein Xis O.13. The oligonucleotide of wherein Xis S.14. The oligonucleotide of wherein Xis CHor CF.15. The oligonucleotide of wherein the oligonucleotide comprises:1-20 first-type regions, each first-type region independently comprising 1-20 contiguous nucleosides wherein each nucleoside of each first-type region comprises a first-type modification;0-20 second-type regions, each second-type region independently comprising 1-20 contiguous nucleosides wherein each nucleoside of each second-type region comprises a second-type modification; and0-20 third-type regions, each third-type region independently comprising 1-20 contiguous nucleosides wherein each nucleoside of each third-type region comprises a third-type modification;{'sub': 3', '2', '3, 'wherein the first-type modification, the second-type modification, and the third-type modification are each independently selected from the group consisting of 2′-F, 2′-OCH, 2′-O(CH)2OCH, BNA, F-HNA, 2′-H and 2′-OH.'}16. The oligonucleotide of claim 5 , wherein the oligonucleotide comprises at least one non-phosphodiester internucleoside linkage.17. The oligonucleotide of claim 16 , wherein at least one of the non-phosphodiester internucleoside linkage is selected from the group consisting of phosphorothioate claim 16 , phosphorodithioate claim 16 , alkyl- ...

Подробнее
15-08-2013 дата публикации

TETRAHYDROPYRAN NUCLEIC ACID ANALOGS

Номер: US20130211064A1
Принадлежит: Isis Pharmaceuticals, Inc.

The present disclosure describes tetrahydropyran nucleoside analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, tetrahydropyran nucleoside analogs are provided, having one or more chiral substituents, that are useful for enhancing properties of oligomeric compounds including nuclease resistance and binding affinity. In some embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. 2. The oligomeric compound of wherein at least one of the monomer subunits is a modified nucleoside.3. The oligomeric compound of wherein each of the modified nucleosides is claim 2 , independently claim 2 , selected from bicyclic nucleosides claim 2 , 2′-modified nucleosides claim 2 , 4′-thio modified nucleosides and 4′-thio-2′-modified nucleosides.4. The oligomeric compound of wherein each of the 2′-modified nucleosides comprises a 2′-substituent group independently selected from 2′-F claim 3 , 2′-OCHand 2′-O(CH)—OCH.5. The oligomeric compound of wherein each of the modified nucleosides is claim 3 , a bicyclic nucleoside.7. The oligomeric compound of comprising at least one 5′ or 3′-terminal group.8. The oligomeric compound of wherein at least one of the 5′ and 3′-terminal groups is a linked conjugate group.9. The oligomeric compound of wherein each of the monomer subunits that is not a tetrahydropyran nucleoside analog of said formula is a β-D-2′-deoxyribonucleoside.10. The oligomeric compound of wherein each of the monomer subunits that is not a tetrahydropyran nucleoside analog of said formula or a modified nucleoside is a β-D-2′-deoxyribonucleoside.11. The oligomeric compound of wherein each of the monomer subunits comprises a heterocyclic base moiety independently selected from uracil claim 1 , thymine claim 1 , cytosine claim 1 , adenine or guanine.12. The oligomeric compound of wherein each cytosine heterocyclic base optionally ...

Подробнее
03-10-2013 дата публикации

Conformationally restricted dinucleotide monomers and oligonucleotides

Номер: US20130260460A1
Принадлежит: ISIS PHARMACEUTICALS INC

This invention relates to conformationally locked dinucleotide motifs for exo- and phosphate stabilization. For instance, oligonucleotides can be prepared having one or more of the following formulas (IV-IX).

Подробнее
05-12-2013 дата публикации

5'-END DERIVATIVES

Номер: US20130323836A1
Принадлежит: Isis Pharmaceuticals, Inc.

The present invention provides compounds of formula (1). Another aspect of the invention relates to a method of inhibiting the expression of a gene in call, the method comprising (a) contacting an oligonucleotide of the invention with the cell; and (b) maintaining the cell from step (a) for a time sufficient to obtain degradation of the mRNA of the target gene. 13-. (canceled)68-. (canceled)9. The compound of wherein Y′ and Y″ are independently for each occurrence (CH)OH claim 4 , (CH)SCH claim 4 , (CH)SH claim 4 , COR claim 4 , (CH)COR claim 4 , (CH)NQQ claim 4 , OP(Z)(Y)NQQ claim 4 , OP(Z)(X)Y claim 4 , linear or branched alkyl claim 4 , aryl claim 4 , heteroaryl claim 4 , or heterocyclic.10. The compound of wherein n is 1-4.11. (canceled)12. The compound of wherein Ris OH or alkoxy.1317-. (canceled)18. The compound of wherein Zis oligonucleotide.19. An oligonucleotide comprising at least one compound of .20. (canceled)21. The oligonucleotide of wherein the oligonucleotide comprises:1-20 first-type regions, each first-type region independently comprising 1-20 contiguous nucleosides wherein each nucleoside of each first-type region comprises a first-type modification;0-20 second-type regions, each second-type region independently comprising 1-20 contiguous nucleosides wherein each nucleoside of each second-type region comprises a second-type modification; and0-20 third-type regions, each third-type region independently comprising 1-20 contiguous nucleosides wherein each nucleoside of each third-type region comprises a third-type modification,{'sub': 3', '2', '3, 'wherein the first-type modification, the second-type modification, and the third-type modification are each independently selected from 2′-F, 2′-OCH, 2′-0(CH)2OCH, BNA, F—HNA, 2′-H and 2′-OH.'}22. The oligonucleotide of claim 19 , wherein the oligonucleotide comprises at least one non-phosphodiester internucleoside linkage.23. The oligonucleotide of claim 22 , wherein the non-phosphodiester internucleoside ...

Подробнее
27-02-2014 дата публикации

OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS

Номер: US20140057963A1
Принадлежит: REGULUS THERAPEUTICS INC.

Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided. 1. (canceled)2. A compound comprising a first oligomeric compound and a second oligomeric compound , wherein the first oligomeric compound consists of 17 to 25 monomeric subunits and is at least 90% identical to the sequence of miR-16 (SEQ ID NO: 196) and wherein the second oligomeric compound consists of 17 to 25 monomeric subunits and is at least 80% complementary to the sequence of the first oligomeric compound , and wherein at least one monomeric subunit of the second oligomeric compound is a modified nucleoside.3. The compound of claim 2 , wherein the first oligomeric compound is at least 95% identical to the sequence of miR-16 (SEQ ID NO: 196).4. The compound of claim 2 , wherein the second oligomeric compound is at least 85% complementary to the sequence of the first oligomeric compound.5. The compound of claim 2 , wherein the second oligomeric compound is at least 90% complementary to the sequence of the first oligomeric compound.6. The compound of claim 2 , wherein the first oligomeric compound and/or the second oligomeric compound comprises a 5′-terminal modification.7. The compound of claim 2 , wherein the second oligomeric compound comprises a 5′-terminal modification.8. The compound of claim 6 , wherein the 5′-terminal modification is a 5′-modified phosphate.9. The compound of claim 2 , wherein the first oligomeric compound and/or the second oligomeric compound comprises a two-nucleobase overhang at the 3′ end.10. The compound of claim 9 , wherein the first oligomeric compound and the second oligomeric compound each comprises a two-nucleobase ...

Подробнее
13-03-2014 дата публикации

CYCLOHEXENYL NUCLEIC ACIDS ANALOGS

Номер: US20140073786A1
Принадлежит: Isis Pharmaceuticals, Inc.

The present disclosure describes cyclohexenyl nucleic acid analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, cyclohexenyl nucleic acid analogs are provided, having one or more chiral substituents, that are expected to be useful for enhancing properties of oligomeric compounds including nuclease resistance and binding affinity. In some embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. 2. The cyclohexenyl nucleic acid analog of wherein q claim 1 , q claim 1 , qand qare each H.3. The cyclohexenyl nucleic acid analog of wherein at least one of q claim 1 , q claim 1 , qand qis substituted C-Calkyl.4. The cyclohexenyl nucleic acid analog of wherein at least one of q claim 1 , q claim 1 , qand qis substituted C-Calkyl comprising at least one substituent group selected from fluoro or OCH.5. The cyclohexenyl nucleic acid analog of wherein at least one of q claim 1 , q claim 1 , qand qis C-Calkyl.6. The cyclohexenyl nucleic acid analog of wherein at least one of q claim 1 , q claim 1 , qand qis methyl.7. The cyclohexenyl nucleic acid analog of wherein j claim 1 , j claim 1 , jand jare each H.8. The cyclohexenyl nucleic acid analog of wherein at least one of j claim 1 , j claim 1 , jand jis substituted C-Calkyl.9. The cyclohexenyl nucleic acid analog of wherein at least one of j claim 1 , j claim 1 , jand jis substituted C-Calkyl comprising at least one substituent group selected from fluoro or OCH.10. The cyclohexenyl nucleic acid analog of wherein at least one of j claim 1 , j claim 1 , jand jis C-Calkyl.11. The cyclohexenyl nucleic acid analog of wherein at least one of j claim 1 , j claim 1 , jand jis methyl or fluoro.12. The cyclohexenyl nucleic acid analog of wherein at least one of j claim 1 , j claim 1 , jand jis fluoro.13. The cyclohexenyl nucleic acid analog of wherein q claim 1 , q claim 1 , q claim 1 , q ...

Подробнее
04-01-2018 дата публикации

COMPOSITIONS AND METHODS

Номер: US20180002693A1
Принадлежит: Ionis Pharmaceuticals, Inc.

Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine. 240-. (canceled)41. The compound of claim 1 , wherein the modified oligonucleotide comprises at least one modified sugar.42. The compound of claim 41 , wherein the modified sugar is a bicyclic sugar.43. The compound of claim 42 , wherein the bicyclic sugar is selected from the group consisting of: 4′-(CH)—O-2′ (LNA); 4′-(CH)—O-2′ (ENA); and 4′-CH(CH)—O-2′ (cEt).44. The compound of claim 42 , wherein the modified sugar is 2′-O-methoxyethyl.45. The compound of claim 1 , wherein the modified oligonucleotide comprises at least one modified nucleobase.46. The compound of claim 45 , wherein the modified nucleobase is a 5-methylcytosine.4754-. (canceled)55. The compound of claim 1 , wherein the compound is single-stranded.56. The compound of claim 1 , wherein the compound is double-stranded.57. The compound of claim 1 , wherein the modified oligonucleotide comprises at least one modified internucleoside linkage.58. The compound of claim 57 , wherein the modified internucleoside linkage is a phosphorothioate internucleoside linkage.59. The compound of claim 57 , wherein the modified oligonucleotide comprises at least one phosphodiester internucleoside linkage.60213-. (canceled)214. A composition comprising the compound of or salt thereof and at least one of a pharmaceutically acceptable carrier or diluent.215. A prodrug comprising the compound of .216. A method comprising administering to an animal the compound or composition of .217. The method of claim 216 , wherein the animal is a human.218. The method of claim 216 , comprising co-administering the compound or composition and a second agent.219. (canceled) The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled BIOL0255USC1SEQ_ST25.txt created Jun. 8, 2017, which is 504 Kb in size. ...

Подробнее
07-01-2021 дата публикации

Selective Antisense Compounds and Uses Thereof

Номер: US20210002636A1
Принадлежит: Ionis Pharmaceuticals, Inc.

The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount, activity, or expression of the target nucleic acid in a cell. In certain embodiments, hybridization results in selective modulation of the amount, activity, or expression of a target Huntingtin gene or Huntingtin transcript in a cell. 120.-. (canceled)21. A compound comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides , wherein the linked nucleosides comprise at least 8 contiguous nucleobases of a nucleobase sequence recited in SEQ ID NO: 5 , 6 , 27 , 28 , 29 , 30 , 38 , 39 , or 46 , wherein the modified oligonucleotide has a sugar motif selected from ekek-d9-keke , kekk-d8-keke , ekkk-d8-kke , ekk-d8-kkke , ekekk-d8-keke , ekek-d8-kkeke , eekk-d8-kkeee , eekk-d8-kkeee , and eeekk-d8-kkee , wherein k is a nucleoside comprising a cEt sugar moiety , e is a nucleoside comprising a 2′-O-methoxyethyl sugar moiety , and d is a 2′-deoxynucleoside.22. The compound of claim 21 , wherein the nucleobase sequence of the modified oligonucleotide is 100% complementary to SEQ ID NO. 1.23. The compound of claim 22 , wherein the modified oligonucleotide has the nucleobase sequence recited in SEQ ID NO: 5.24. The compound of claim 22 , wherein the modified oligonucleotide has the nucleobase sequence recited in SEQ ID NO: 6.25. The compound of claim 22 , wherein the modified oligonucleotide has the nucleobase sequence recited in SEQ ID NO: 27.26. The compound of claim 22 , wherein the modified oligonucleotide has the nucleobase sequence recited in SEQ ID NO: 28.27. The compound of claim 22 , wherein the modified oligonucleotide has the nucleobase sequence recited in SEQ ID NO: 29.28. The compound of claim 22 , wherein the modified oligonucleotide has the nucleobase sequence recited in ...

Подробнее
03-01-2019 дата публикации

Selective reduction of allelic variants

Номер: US20190002877A1
Принадлежит: Ionis Pharmaceuticals Inc

Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate diseases, including neurodegenerative diseases, such as Huntington's Disease (HD).

Подробнее
27-01-2022 дата публикации

CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE

Номер: US20220023429A1
Принадлежит: Ionis Pharmaceuticals, Inc.

The present disclosure provides duplexes comprising a first oligomeric compound and a second oligomeric compound wherein the second oligomeric compound comprises a conjugate group. In certain embodiments, the duplex modulates the amount or activity of a target nucleic acid in extra hepatic tissues and/or extra hepatic cells. In certain embodiments, the duplex modulates the amount or activity of a target nucleic acid in hepatic tissues and/or hepatic cells. 1377-. (canceled)378. A duplex comprising a first oligomeric compound and a second oligomeric compound wherein:the first oligomeric compound comprises a first modified oligonucleotide consisting of 10-30 linked nucleosides, having a nucleobase sequence that is at least 80% complementary to the nucleobase sequence of the second oligomeric compound and that is at least 80% complementary to an extra-hepatic nucleic acid target;wherein neither the first oligomeric compound nor the duplex is an RNAi compound; wherein the conjugate group comprises a conjugate moiety and a conjugate linker,', 'wherein the conjugate moiety is cholesterol; and wherein the conjugate linker comprises at least one cleavable moiety; and', 'wherein the extra-hepatic nucleic acid target is expressed in the brain or spinal cord., 'the second oligomeric compound comprises a conjugate group and a second modified oligonucleotide consisting of 10-30 linked nucleosides;'}379. The duplex of claim 378 , wherein the first modified oligonucleotide comprises at least one modified nucleoside.380. The duplex of claim 379 , wherein the at least one modified nucleoside of the first modified oligonucleotide comprises a bicyclic sugar moiety.381. The duplex of claim 380 , wherein at least one bicyclic sugar moiety comprises a 2′-4′ bridge claim 380 , wherein the 2′-4′ bridge is selected from —O—CH—; and —O—CH(CH)—.382. The duplex of claim 379 , wherein the at least one modified nucleoside of the first modified oligonucleotide comprises a non-bicyclic sugar ...

Подробнее
08-01-2015 дата публикации

COMPOSITIONS AND METHODS FOR OPTIMIZING CLEAVAGE OF RNA BY RNASE H

Номер: US20150011001A1
Принадлежит: Isis Pharmaceuticals, Inc.

The present invention provides compositions and methods for the optimization of cleavage of RNA species by RNase H. In some embodiments, the invention provides oligonucleotides that possess two or more regions of differing conformation, and at least one transitional nucleobase positioned between the regions that is capable of modulating transfer of the helical conformation characteristic of the region bound to the 3′ hydroxy thereof, to the region bound to the 5′ hydroxyl thereof. 132.-. (canceled)33. A method of modulating the concentration of a targeted RNA molecule in a eukaryotic cell comprising the step of contacting said cell with an oligonucleotide havinga) a first region of nucleotides of one conformation which, when bound to said targeted RNA, forms a substrate for cleavage by an RNase;b) a second region of nucleotides having a different conformation which, when bound to said targeted RNA molecule does not form a substrate for cleavage by an RNase, andc) a transition moiety which modulates the transmission of the conformation of said second region into said first region.34. The method of claim 33 , wherein the first region comprises deoxynucleotides.35. The method of claim 34 , wherein the second region comprises 2′-O-alkoxyalkyl ribonucleotides.36. The method of claim 35 , wherein the 2′-O-alkoxyalkyl ribonucleotides are 2′-O-methoxyethyl ribonucleotides.37. The method of claim 36 , wherein the internucleotide linkages in the first or second regions are phosphorothioates.38. The method of claim 36 , further comprising a third region of nucleotides having a conformation different than the conformation of said first region claim 36 , said third region is positioned 3′ to said first region and when bound to said targeted RNA molecule does not form a substrate for cleavage by an RNase.39. The method of claim 38 , wherein said third region has the same conformation as the second region.40. The method of claim 39 , wherein the transition moiety is interspersed ...

Подробнее
14-01-2016 дата публикации

OLIGOMERIC COMPOUNDS AND EXCIPIENTS

Номер: US20160010086A1
Принадлежит: Isis Pharmaceuticals, Inc.

The present invention provides method of optimizing the efficacy and potency of antisense compounds. In certain embodiments, the invention provides assays useful for determining favorable oligonucleotide characteristics and excipients for improved cellular uptake. 163-. (canceled)64. A pharmaceutical composition comprising an antisense oligonucleotide; at least one excipient , and purified water or saline solution , wherein at least one excipient is an oligosaccharide or polysaccharide.65. The pharmaceutical composition of claim 64 , wherein at least one excipient is a branched oligosaccharide or branched polysaccharide.66. The pharmaceutical composition of claim 64 , wherein at least one excipient is a glucan or glucan derivative.67. The pharmaceutical composition of claim 66 , wherein at least one excipient is a dextran or dextran derivative.68. The pharmaceutical composition of claim 67 , wherein at least one excipient is selected from: dextran phenyl carbonate claim 67 , dextran ethyl carbonate claim 67 , dextran tributyrate claim 67 , dextran tripropionate claim 67 , dextran tributyrate claim 67 , dextran benzyl ether claim 67 , dextran triacetate claim 67 , dextran triheptanoate claim 67 , dextran butyl carbamate.69. The pharmaceutical composition of claim 67 , wherein at least one excipient is selected from a dextran ester claim 67 , caproyldextran claim 67 , stearyldextran claim 67 , lauryldextran claim 67 , and acetyldextran.70. The pharmaceutical composition of claim 67 , wherein at least one excipient is an ether of dextran.71. The pharmaceutical composition of claim 70 , wherein at least one excipient is sulfopropyl ether of dextran claim 70 , phosphonomethyl ether of dextran claim 70 , mercaptoethyl ether of dextran claim 70 , 3-chloro-2-hydroxypropyl ether of dextran claim 70 , cyanoethyl ether of dextran claim 70 , or 2-(3′-amino-4′-methoxyphenyl)-sulfonylethyl ether of dextran.72. The pharmaceutical composition of claim 67 , wherein at least one ...

Подробнее
21-01-2016 дата публикации

CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE

Номер: US20160017323A1
Принадлежит: Isis Pharmaceuticals, Inc.

Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine. 1296.-. (canceled)298. The compound of claim 297 , wherein X is S.299. The compound of claim 297 , wherein Q or Qis OCH.300. The compound of claim 297 , wherein Q or Qis O(CH)—OCH.301. The compound of claim 300 , wherein Qis O(CH)—OCH302. The compound of claim 297 , wherein Tis selected from among: GalNAc-1a claim 297 , GalNAc-2a claim 297 , GalNAc-3a claim 297 , GalNAc-4a claim 297 , GalNAc-5a claim 297 , GalNAc-6a claim 297 , GalNAc-7a claim 297 , GalNAc-8a claim 297 , GalNAc-9a claim 297 , GalNAc-10a claim 297 , GalNAc-11a claim 297 , GalNAc-12a claim 297 , GalNAc-13a claim 297 , GalNAc-14a claim 297 , GalNAc-15a claim 297 , GalNAc-16a claim 297 , GalNAc-17a claim 297 , GalNAc-18a claim 297 , GalNAc-19a claim 297 , GalNAc-20a claim 297 , GalNAc-21a claim 297 , GalNAc-22a claim 297 , GalNAc-23a claim 297 , GalNAc-24a claim 297 , GalNAc-25a claim 297 , GalNAc-26a claim 297 , GalNAc-27a claim 297 , GalNAc-28a claim 297 , GalNAc-29a claim 297 , GalNAc-30a claim 297 , GalNAc-31a claim 297 , and GalNAc-32a.303. The compound of claim 298 , wherein Tis selected from among: GalNAc-1a claim 298 , GalNAc-2a claim 298 , GalNAc-3a claim 298 , GalNAc-4a claim 298 , GalNAc-5a claim 298 , GalNAc-6a claim 298 , GalNAc-7a claim 298 , GalNAc-8a claim 298 , GalNAc-9a claim 298 , GalNAc-10a claim 298 , GalNAc-11a claim 298 , GalNAc-12a claim 298 , GalNAc-13a claim 298 , GalNAc-14a claim 298 , GalNAc-15a claim 298 , GalNAc-16a claim 298 , GalNAc-17a claim 298 , GalNAc-18a claim 298 , GalNAc-19a claim 298 , GalNAc-20a claim 298 , GalNAc-21a claim 298 , GalNAc-22a claim 298 , GalNAc-23a claim 298 , GalNAc-24a claim 298 , GalNAc-25a claim 298 , GalNAc-26a claim 298 , GalNAc-27a claim 298 , GalNAc-28a claim 298 , GalNAc-29a claim 298 , GalNAc-30a claim 298 , GalNAc-31a claim 298 , and GalNAc-32a.304. The compound of claim 299 , wherein ...

Подробнее
21-01-2016 дата публикации

CHIMERIC OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE MODULATION

Номер: US20160017324A1
Принадлежит: Isis Pharmaceuticals, Inc.

Oligomer compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers includes at least one nucleotide comprising a chimeric organic composition. Oligomer/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex (RISC), wherein at least one nucleotide comprising a chimeric organic composition.

Подробнее
21-01-2016 дата публикации

DOUBLE STRAND COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENE MODULATION

Номер: US20160017328A1
Принадлежит: Isis Pharmaceuticals, Inc.

The present invention provides double stranded compositions wherein each strand is modified to have a motif defined by positioning of β-D-ribonucleosides and sugar modified nucleosides. More particularly, the present compositions comprise one strand having an alternating motif and another strand having a hemimer motif, a blockmer motif, a fully modified motif or a positionally modified motif. At least one of the strands has complementarity to a nucleic acid target. The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes. In preferred embodiments the compositions of the present invention hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. The present invention also provides methods for modulating gene expression. 1. A composition comprising first and second chemically synthesized oligomeric compounds wherein:at least a portion of the first oligomeric compound is complementary to and capable of hybridizing to a selected nucleic acid target;a portion of from about 12 to about 24 nucleosides of the first oligomeric compound is complementary to the second oligomeric compound; {'br': None, 'sub': n', 'nn, '5′-A(-L-B-L-A)(-L-B)-3′'}, 'one of the first and the second oligomeric compounds comprises nucleosides linked by internucleoside linking groups wherein the sequence of linked nucleosides defines an alternating motif having the formula each L is, independently, an internucleoside linking group;', 'each A is a sugar modified nucleoside and each sugar modification of each A nucleoside is identical;', 'each B is a sugar modified nucleoside and each sugar modification of each B nucleoside is identical;', 'the sugar modification of each A is different than the sugar modification of each B;', 'n is from about 7 to about 11;', 'nn is 0 or 1;, 'whereinthe other of the first and the second oligomeric compound is a fully modified oligomeric compound comprising a ...

Подробнее
21-01-2016 дата публикации

OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS

Номер: US20160017329A1
Принадлежит:

Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided. 12.-. (canceled)3. A method of inhibiting the activity , function , or amount of miR-155 (SEQ ID NO: 283) , comprising contacting a cell with a compound comprising a modified oligonucleotide , wherein:the modified oligonucleotide consists of 8, 9, 10, 11, or 12 linked monomeric subunits;each monomeric subunit of the modified oligonucleotide comprises a modified sugar moiety; andthe modified oligonucleotide is complementary to miR-155 with no more than one mismatch.4. The method of wherein the modified oligonucleotide consists of 8 monomeric subunits.5. The method of wherein the modified oligonucleotide consists of 9 monomeric subunits.6. The method of wherein the modified oligonucleotide consists of 10 monomeric subunits.7. The method of wherein the modified oligonucleotide consists of 11 monomeric subunits.8. The method of wherein the modified oligonucleotide consists of 12 monomeric subunits.9. The method of claim 3 , wherein each modified sugar moiety is independently selected from a 2′-F sugar moiety claim 3 , a 2′-O-methyl sugar moiety claim 3 , a 2′-O-methoxyethyl sugar moiety claim 3 , and a bicyclic sugar moiety.10. The method of claim 9 , wherein the bicyclic sugar moiety has a 4′-CH—O-2′ bridge.11. The method of claim 3 , wherein the modified oligonucleotide comprises at least one modified internucleoside linkage.12. The method of claim 11 , wherein the modified internucleoside linkage is a phosphorothioate linkage.13. The method of claim 3 , wherein each internucleoside linkage of the modified oligonucleotide is a phosphorothioate linkage.14. ...

Подробнее
15-01-2015 дата публикации

OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE

Номер: US20150018540A1
Принадлежит: Isis Pharmaceuticals, Inc.

Oligonucleotides, chemically-modified oligonucleotides, and oligonucleotide-conjugate compl in research, diagnostics, and/or therapeutics are described herein. 1529.-. (canceled)533. The compound of claim 530 , wherein the conjugate group is attached to the oligonucleotide at a nucleoside at position 1 claim 530 , 2 claim 530 , 3 claim 530 , 4 claim 530 , 6 claim 530 , 7 claim 530 , 8 claim 530 , 9 claim 530 , 18 claim 530 , 19 claim 530 , 20 claim 530 , or 21 from the 5′-end of the oligonucleotide or at position 1 claim 530 , 2 claim 530 , 3 claim 530 , 12 claim 530 , 13 claim 530 , 4 claim 530 , 15 claim 530 , 17 claim 530 , 18 claim 530 , 19 claim 530 , 20 claim 530 , or 21 from the 3′-end of the oligonucleotide.534. The compound of claim 533 , wherein the conjugate group is attached to any of the 1 to 4 5′-most nucleosides of the oligonucleotide.535. The compound of claim 533 , wherein the conjugate group is attached to the 5′-terminal nucleoside of the oligonucleotide.536. The compound of claim 533 , wherein the conjugate group is to the 8nucleoside from the 5′-terminal end of the oligonucleotide.537. The compound of claim 533 , wherein the conjugate group is attached to the 6nucleoside from the 5′-terminal end of the oligonucleotide.538. The compound of claim 533 , wherein the conjugate group comprises Calkyl.539. The compound of claim 533 , wherein the conjugate group comprises Calkyl.540. The compound of claim 533 , wherein the conjugate group comprises Calkyl.541. The compound of claim 533 , wherein the conjugate group comprises a steroid.542. The compound of claim 533 , wherein the conjugate group comprises cholesterol.543. The compound of claim 533 , wherein the conjugate group comprises a carbohydrate.544. The compound of claim 533 , wherein the conjugate group comprises N-Acetylgalactosamine.545. The compound of claim 533 , wherein each nucleoside is a modified nucleoside.546. The compound of claim 533 , comprising at least one 2′-modified nucleosides. ...

Подробнее
17-01-2019 дата публикации

COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION

Номер: US20190016748A1
Принадлежит: Ionis Pharmaceuticals, Inc.

Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids and/or glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease and/or metabolic disease, or a symptom thereof, in an individual in need thereof. 126.-. (canceled)28. The compound of claim 27 , wherein the nucleobase sequence of the modified oligonucleotide is at least 85% claim 27 , at least 90% claim 27 , at least 95% claim 27 , or 100% complementary to SEQ ID NOs: 1.29. The compound of claim 27 , wherein the modified oligonucleotide comprises at least one modified internucleoside linkage.30. The compound of claim 29 , wherein the modified internucleoside linkage is a phosphorothioate internucleoside linkage.31. The compound of claim 27 , wherein the modified oligonucleotide comprises at least one modified sugar.32. The compound of claim 31 , wherein at least one modified sugar is selected from a bicyclic sugar claim 31 , a 2′-O-methoxyethyl modified sugar claim 31 , a constrained ethyl modified sugar claim 31 , a 3′-fluoro-HNA or a 4′-(CH)—O-2′ bridge claim 31 , wherein n is 1 or 2.33. The compound of claim 27 , wherein at least one nucleoside comprises a modified nucleobase.34. The compound of claim 33 , wherein the modified nucleobase is a 5-methylcytosine.35. The compound of claim 27 , wherein the modified oligonucleotide comprises:a gap segment consisting of linked deoxynucleosides;a 5′ wing segment consisting of linked nucleosides;a 3′ wing segment consisting of linked nucleosides;wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.36. The compound claim 27 , wherein the modified oligonucleotide comprises:a gap segment consisting of ten linked ...

Подробнее
21-01-2021 дата публикации

MODIFIED COMPOUNDS AND USES THEREOF

Номер: US20210017513A1
Принадлежит: Ionis Pharmaceuticals, Inc.

The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose. 1. An oligomeric compound comprising a modified oligonucleotide consisting of 14 to 16 linked nucleosides , wherein the modified oligonucleotide has a 5′-region , a central region , and a 3′-region , wherein:the 5′-region consists of 1-3 linked nucleosides, each comprising a 4′-to-2′ linked bicyclic sugar moiety;the 3′ region consists of 1-3 linked nucleosides, each comprising a 4′-to-2′ linked bicyclic sugar moiety; {'br': None, 'sub': d', 'x', 'd', 'n, '(N)(N)(N)'}, 'and the central region consists of 9-10 linked nucleosides, wherein the central region has the following formula{'sub': x', 'd, 'wherein Nis a nucleoside comprising a 2′-OMe-β-D-ribofuranosyl sugar moiety and each Nis a nucleoside comprising a 2′-β-D-deoxyribosyl sugar moiety;'}and n is 7 or 8.2. The oligomeric compound of claim 1 , wherein the 5′ region consists of 3 nucleosides.3. The oligomeric compound of or claim 1 , wherein the 3′ region consists of 3 nucleosides.4. The oligomeric compound of any of - claim 1 , wherein each 4′-to-2′ linked bicyclic sugar moiety of each nucleoside of the 5′ region is independently selected from cEt claim 1 , LNA claim 1 , and ENA.5. The oligomeric compound of any of - claim 1 , wherein each 4′-to-2′ linked bicyclic sugar moiety of each nucleoside of the 3′ region is independently selected from cEt claim 1 , LNA claim 1 , and ENA.6. The oligomeric compound of any of - claim 1 , wherein each 2′-4′ bicyclic sugar moiety of each nucleoside of the 3′ region and the 5′ region is a cEt.7. The oligomeric compound of any of - claim 1 , wherein each nucleobase of each nucleoside of the modified oligonucleotide is independently selected from among thymine claim 1 , uracil ...

Подробнее
16-01-2020 дата публикации

COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION

Номер: US20200017855A1
Принадлежит: Ionis Pharmaceuticals, Inc.

The present invention provides compositions comprising at least one oligomeric compound comprising an alternating motif and further include a region that is complementary to a nucleic acid target. The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes. In preferred embodiments the compositions of the present invention hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. The present invention also provides methods for modulating gene expression. 1105.-. (canceled)106. A composition comprising a first oligomeric compound and a second oligomeric compound , wherein:at least a portion of said first oligomeric compound is capable of hybridizing with at least a portion of said second oligomeric compound;at least a portion of said first oligomeric compound is complementary to and capable of hybridizing to a selected nucleic acid target;{'sub': 1', '2', '1', '2', '3, 'at least one of said first and said second oligomeric compounds comprises a region having the formula X—Y—X, wherein Y is a region of from about 5 to about 12 linked nucleosides and each of Xand Xis, independently, a plurality of linked nucleosides having the formula FSFS, where one of F and S is a 2′-F modified nucleoside and the other of F and S is a 2′-O—CHmodified nucleoside; and'}each of the linked nucleosides is, independently, linked by a phosphodiester or a phosphorothioate internucleoside linkage.107. The composition of wherein said first oligomeric compound comprises a 5′-phosphate group.108. The composition of wherein said second oligomeric compound comprises a 5′-phosphate group.109. The composition of wherein each of said first and said second oligomeric compounds comprise a 5′-phosphate group.110. The composition of wherein at least one of said first and said second oligomeric compounds comprises at least one conjugate group.111. The composition of wherein at least one of said first and ...

Подробнее
17-04-2014 дата публикации

SUBSTITUTED 2'-THIO-BICYCLIC NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM

Номер: US20140106451A1
Принадлежит:

Provided herein are novel bicyclic nucleosides, oligomeric compounds that include such bicyclic nucleosides and methods of using the oligomeric compounds. More particularly, the novel bicyclic nucleosides comprise a furanose ring system having a bridge comprising a 4′-methylene group attached to a 2′-sulfoxide or sulfone group and optionally including one or more substituent groups attached to the 4′-methylene and or the 5′-position. In certain embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. 2. The bicyclic nucleoside of wherein Bx is an optionally protected pyrimidine claim 1 , substituted pyrimidine claim 1 , purine or substituted purine.3. The bicyclic nucleoside of wherein Bx is uracil claim 2 , thymine claim 2 , cytosine claim 2 , 4-N-benzoylcytosine claim 2 , 5-methylcytosine claim 2 , 4-N-benzoyl-5-methylcytosine claim 2 , adenine claim 2 , 6-N-benzoyladenine claim 2 , guanine or 2-N-isobutyrylguanine.4. The bicyclic nucleoside of wherein at least one of Q claim 1 , Q claim 1 , Gand Gis CHand the remaining of Q claim 1 , Q claim 1 , Gand Gare each H.5. The bicyclic nucleoside of wherein Q claim 1 , Q claim 1 , Gand Gare each H.6. The bicyclic nucleoside of wherein Tis 4 claim 1 ,4′-dimethoxytrityl and Tis diisopropylcyanoethoxy phosphoramidite.7. The bicyclic nucleoside of wherein n is 1 and the configuration at the sulfur atom is R.8. The bicyclic nucleoside of wherein n is 1 and the configuration at the sulfur atom is S.9. The bicyclic nucleoside of wherein n is 2.10. The bicyclic nucleoside of wherein Q claim 1 , Q claim 1 , Gand Gare each H claim 1 , Tis 4 claim 1 ,4′-dimethoxytrityl and Tis diisopropylcyanoethoxy phosphoramidite.12. The oligomeric compound of wherein each Bx is claim 11 , independently claim 11 , uracil claim 11 , thymine claim 11 , cytosine claim 11 , 4-N-benzoylcytosine claim 11 , 5-methylcytosine claim 11 , 4-N-benzoyl- ...

Подробнее
17-04-2014 дата публикации

MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION

Номер: US20140107184A1
Принадлежит: Isis Pharmaceuticals, Inc.

Disclosed herein are antisense compounds and methods for decreasing HBV mRNA, DNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate HBV-related diseases, disorders or conditions. 1. A compound comprising a single-stranded modified oligonucleotide consisting of the sequence recited in any one of SEQ ID NOs: 17 , 50 , 722 , 1327 , 1340 , and 1379 , wherein the modified oligonucleotide is 100% complementary over its entire length with a nucleic acid encoding hepatitis B virus (HBV) and comprises:a gap segment consisting of linked deoxynucleosides;a 5′ wing segment consisting of linked nucleosides; anda 3′ wing segment consisting of linked nucleosides;wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.2. The compound of claim 1 , wherein the modified oligonucleotide comprises at least one modified internucleoside linkage.3. The compound of claim 2 , wherein each internucleoside linkage is a phosphorothioate internucleoside linkage.4. The compound of claim 1 , wherein the modified sugar is a bicyclic sugar.5. The compound of claim 4 , wherein the bicyclic sugar comprises a 4′-CH(CH3)-O-2′ group.6. The compound of claim 1 , wherein the at least one modified sugar comprises a 2′-O-methoxyethyl group.7. The compound of claim 1 , wherein at least one nucleoside comprises a modified nucleobase.8. The compound of claim 7 , wherein the modified nucleobase is a 5-methylcytosine.9. The compound of claim 1 , wherein the oligonucleotide consists of 17 linked nucleosides having a nucleobase sequence consisting of the sequence recited in SEQ ID NO: 17 claim 1 , and wherein the oligonucleotide comprises:a gap segment consisting of 10 linked deoxynucleosides;a 5′ wing segment consisting of 3 linked nucleosides; anda 3′ wing segment consisting of 4 linked nucleosides;wherein the gap segment is positioned between ...

Подробнее
17-04-2014 дата публикации

Oligomeric compounds comprising bicyclic nucleotides and uses thereof

Номер: US20140107330A1
Принадлежит: ISIS PHARMACEUTICALS INC

The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.

Подробнее
28-01-2021 дата публикации

COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION

Номер: US20210024923A1
Принадлежит: Ionis Pharmaceuticals, Inc.

Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine. 133-. (canceled)3539-. (canceled)40. The method of claim 34 , wherein the transthyretin amyloidosis is senile systemic amyloidosis (SSA).41. The method of claim 34 , wherein the transthyretin amyloidosis is familial amyloid polyneuropathy (FAP).42. The method of claim 34 , wherein the transthyretin amyloidosis is familial amyloid cardiopathy (FAC). The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled BIOL0248USC5SEQ_ST25.txt, created on Feb. 13, 2020, which is 20 Kb in size. The information in the electronic format of the sequence listing is incorporated herein by reference in its entirety.The principle behind antisense technology is that an antisense compound hybridizes to a target nucleic acid and modulates the amount, activity, and/or function of the target nucleic acid. For example in certain instances, antisense compounds result in altered transcription or translation of a target. Such modulation of expression can be achieved by, for example, target mRNA degradation or occupancy-based inhibition. An example of modulation of RNA target function by degradation is RNase H-based degradation of the target RNA upon hybridization with a DNA-like antisense compound. Another example of modulation of gene expression by target degradation is RNA interference (RNAi). RNAi refers to antisense-mediated gene silencing through a mechanism that utilizes the RNA-induced siliencing complex (RISC). An additional example of modulation of RNA target function is by an occupancy-based mechanism such as is employed naturally by microRNA. MicroRNAs are small non-coding RNAs that regulate the expression of protein-coding RNAs. The binding of an antisense compound to a microRNA prevents that microRNA from binding to its messenger RNA targets, and ...

Подробнее
29-01-2015 дата публикации

METHODS AND COMPOSITIONS FOR MODULATING FACTOR VII EXPRESSION

Номер: US20150031747A1
Принадлежит: Isis Pharmaceuticals, Inc.

Disclosed herein are antisense compounds and methods for decreasing Factor VII and treating, preventing, or slowing progression of thromboembolic complications, hyperproliferative disorders, or inflammatory conditions in an individual in need thereof. 1. A compound comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides and comprising a nucleobase sequence comprising a portion of at least 8 , at least 10 , at least 12 , at least 14 , at least 16 , at least 18 , at least 19 , or at least 20 contiguous nucleobases complementary to an equal length portion of nucleobases 1381 to 1406 of SEQ ID NO: 1 , wherein the nucleobase sequence of the modified oligonucleotide is at least 90% complementary to SEQ ID NO: 1.2. The compound of claim 1 , wherein the modified oligonucleotide consists of 15 to 30 claim 1 , 18 to 24 claim 1 , 19 to 22 claim 1 , or 20 linked nucleosides.3. A compound comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides and comprising a nucleobase sequence comprising a portion of at least 8 claim 1 , at least 10 claim 1 , at least 12 claim 1 , at least 14 claim 1 , at least 15 claim 1 , or at least 16 contiguous nucleobases complementary to an equal length portion of nucleobases 15128 to 15150 of SEQ ID NO: 1 claim 1 , wherein the nucleobase sequence of the modified oligonucleotide is at least 90% complementary to SEQ ID NO: 1.4. A compound comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides and comprising a nucleobase sequence comprising a portion of at least 8 claim 1 , at least 10 claim 1 , at least 12 claim 1 , at least 14 claim 1 , at least 15 claim 1 , or at least 16 contiguous nucleobases complementary to an equal length portion of nucleobases 2592 to 2607 claim 1 , 2626 to 2641 claim 1 , 2660 to 2675 claim 1 , 2796 to 2811 claim 1 , 2966 to 2981 claim 1 , 3000 to 3015 claim 1 , 3034 to 3049 claim 1 , 3068 to 3083 claim 1 , 3153 to 3168 claim 1 , 3170 to 3185 claim 1 , 3272 ...

Подробнее
06-02-2020 дата публикации

MODULATORS OF DIACYGLYCEROL ACYLTRANSFERASE 2 (DGAT2)

Номер: US20200040341A1
Принадлежит: Ionis Pharmaceuticals, Inc.

The present embodiments provide methods, compounds, and compositions useful for inhibiting DGAT2 expression, which may be useful for treating, preventing, or ameliorating a disease associated with DGAT2. 112-. (canceled)13. A compound comprising a modified oligonucleotide consisting of 15 to 30 linked nucleosides , wherein the modified oligonucleotide is 95% complementary within nucleotides 26778-26797 , 23242-23261 , 26630-26649 , 15251-15270 , 28026-28045 , 35436-35455 , 10820-10836 , 23246-23262 of SEQ ID NO: 2.1419-. (canceled)20. The compound of claim 13 , wherein the modified oligonucleotide comprises at least one modified internucleoside linkage claim 13 , at least one modified sugar claim 13 , or at least one modified nucleobase.21. The compound of claim 20 , wherein the modified internucleoside linkage is a phosphorothioate internucleoside linkage.22. The compound of claim 20 , wherein the modified sugar is a bicyclic sugar.23. The compound of claim 22 , wherein the bicyclic sugar is selected from the group consisting of: 4′-(CH)—O-2′ (LNA); 4′-(CH)—O-2′ (ENA); and 4′—CH(CH)—O-2′ (cEt).24. The compound of claim 20 , wherein the modified sugar is 2′—O-methoxyethyl.25. The compound of claim 20 , wherein the modified nucleobase is a 5-methylcytosine.26. The compound of claim 13 , wherein the modified oligonucleotide comprises:a gap segment consisting of linked deoxynucleosides;a 5′ wing segment consisting of linked nucleosides; anda 3′ wing segment consisting of linked nucleosides;wherein the gap segment is positioned immediately adjacent to and between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.27. The compound of claim 13 , wherein the compound is single-stranded.2833-. (canceled)34. A compound comprising a modified oligonucleotide consisting of 20 linked nucleosides and having a nucleobase sequence consisting of the sequence recited in SEQ ID NO: 1423 claim 13 , wherein the ...

Подробнее
06-02-2020 дата публикации

COMPOSITIONS FOR MODULATING SOD-1 EXPRESSION

Номер: US20200040342A1
Автор: Swayze Eric E.
Принадлежит: Biogen MA Inc.

Disclosed herein are antisense compounds and methods for decreasing SOD-1 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate SOD-1 associated diseases, disorders, and conditions. Such SOD-1 associated diseases include amyotrophic sclerosis (ALS). 1. A compound , comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides and having a nucleobase sequence comprising at least 12 , at least 13 , at least 14 , at least 15 , at least 16 , at least 17 , at least 18 , at least 19 , or at least 20 consecutive nucleobases of any of the nucleobase sequences of SEQ ID NOs: 118-724 or 726-1461.2. (canceled)3. The compound of claim 1 , wherein the modified oligonucleotide has a mixed backbone.4. The compound of claim 3 , wherein the modified oligonucleotide has a mixed backbone wherein the mixed backbone motif is selected from the following:sossssssssoooss,sooossssssssoss,sooosssssssssoss,soosssssssssooss,sooossssssssooss,sooosssssssssooss,sooossssssssssooss,sooosssssssssssooos,soooossssssssssooss,sooosssssssssssooss,sososssssssssssosos, andsooossssssssssoooss, whereins=a phosphorothioate internucleoside linkage, ando=a phosphodiester internucleoside linkage.5. (canceled)6. (canceled)7. (canceled)8. (canceled)9. (canceled)10. (canceled)11. (canceled)12. (canceled)13. (canceled)14. (canceled)15. (canceled)16. (canceled)17. (canceled)18. (canceled)19. (canceled)20. (canceled)21. (canceled)22. (canceled)23. (canceled)24. (canceled)25. (canceled)26. (canceled)27. (canceled)28. (canceled)29. (canceled)30. (canceled)31. (canceled)33. (canceled)34. (canceled)35. (canceled)36. (canceled)37. (canceled)38. (canceled)39. (canceled)40. A compound comprising of a modified oligonucleotide according to the following formula:{'br': None, 'Tes Teo Aeo Aes Tds Gds Tds Tds Tds Ads Tds mCds Ako Gko Ges Aes Te; wherein,'}A=an adenine,mC=a 5-methylcytosineG=a guanine,T=a thymine,e=a 2′-O-methoxyethylribose modified ...

Подробнее
01-05-2014 дата публикации

OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS

Номер: US20140121364A1
Принадлежит: REGULUS THERAPEUTICS INC.

Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided. 1. An oligomeric compound having the nucleobase sequence of SEQ ID NO: 303 , wherein the oligomeric compound comprises 2′-methoxyethoxy (2′-MOE) nucleotides throughout , and wherein each internucleoside linkage is a phosphorothioate linkage.2. An oligomeric compound having the nucleobase sequence of SEQ ID NO: 368 , wherein the oligomeric compound comprises 2′-methoxyethoxy (2′-MOE) nucleotides throughout , and wherein each internucleoside linkage is a phosphorothioate linkage. This application is a divisional of U.S. application Ser. No. 13/540,097, which is a divisional of U.S. application Ser. No. 13/359,271, filed Jan. 26, 2012, now U.S. Pat. No. 8,546,350, which is a continuation of U.S. application Ser. No. 12/346,940, filed Dec. 31, 2008, now U.S. Pat. No. 8,106,025, which is a divisional of U.S. application Ser. No. 10/909,125, filed Jul. 30, 2004, now U.S. Pat. No. 7,683,036, which claims priority to U.S. Provisional Application Nos. 60/492,056, filed Jul. 31, 2003; 60/516,303, filed Oct. 31, 2003; 60/531,596, filed Dec. 19, 2003; and 60/562,417, filed Apr. 14, 2004. Each of the foregoing applications is incorporated herein by reference in its entirety for any purpose.The present invention provides compositions and methods for modulation of small non-coding RNAs. In particular, this invention relates to compounds, particularly oligomeric compounds, which, in some embodiments, hybridize with or sterically interfere with nucleic acid molecules comprising or encoding small non-coding RNA targets. Such compounds are shown herein to modulate the levels ...

Подробнее
01-05-2014 дата публикации

OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS

Номер: US20140121365A1
Принадлежит: REGULUS THERAPEUTICS INC.

Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided. 1. An oligomeric compound having the nucleobase sequence of SEQ ID NO: 303 , wherein the oligomeric compound comprises 2′-methoxyethoxy (2′-MOE) nucleotides throughout , and wherein each internucleoside linkage is a phosphorothioate linkage.2. An oligomeric compound having the nucleobase sequence of SEQ ID NO: 368 , wherein the oligomeric compound comprises 2′-methoxyethoxy (2′-MOE) nucleotides throughout , and wherein each internucleoside linkage is a phosphorothioate linkage. This application is a divisional of U.S. application Ser. No. 12/345,725, filed Dec. 30, 2008, which is a divisional of U.S. application Ser. No. 10/909,125, filed Jul. 30, 2004, now U.S. Pat. No. 7,683,036, which claims priority to U.S. Provisional Application Nos. 60/492,056, filed Jul. 31, 2003; 60/516,303, filed Oct. 31, 2003; 60/531,596, filed Dec. 19, 2003; and 60/562,417, filed Apr. 14, 2004. Each of the foregoing applications is incorporated herein by reference in its entirety for any purpose.The present invention provides compositions and methods for modulation of small non-coding RNAs. In particular, this invention relates to compounds, particularly oligomeric compounds, which, in some embodiments, hybridize with or sterically interfere with nucleic acid molecules comprising or encoding small non-coding RNA targets. Such compounds are shown herein to modulate the levels of small non-coding RNAs. The oligomeric compounds of the invention may include one or more modifications thereon resulting in differences in physical or chemical properties compared to unmodified nucleic ...

Подробнее
18-02-2016 дата публикации

5' MODIFIED NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM

Номер: US20160046939A1
Принадлежит: Isis Pharmaceuticals, Inc.

The present invention provides 5′ modified nucleosides and oligomeric compounds prepared therefrom. More particularly, the present invention provides modified nucleosides having at least one 5′-substituent and an optional 2′ substituent, oligomeric compounds comprising at least one of these modified nucleosides and methods of using the oligomeric compounds. In some embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. 146-. (canceled)48. The composition of claim 47 , wherein Bx is uracil claim 47 , thymine claim 47 , cytosine claim 47 , 5-methylcytosine claim 47 , adenine claim 47 , or guanine.49. The composition of claim 47 , wherein qand qare each claim 47 , independently claim 47 , OCH claim 47 , OCHCHor OC(H)(CH) claim 47 , and qis O.50. The composition of claim 47 , wherein G is halogen claim 47 , OCH claim 47 , OCHF claim 47 , OCHF claim 47 , OCF claim 47 , OCHCH claim 47 , O(CH)F claim 47 , OCHCHF claim 47 , OCHCF claim 47 , OCH—CH═CH claim 47 , O(CH)—OCH claim 47 , O(CH)—SCH claim 47 , O(CH)—OCF claim 47 , O(CH)—N(R)(R) claim 47 , O(CH)—ON(R)(R) claim 47 , O(CH)—O(CH)—N(R)(R) claim 47 , OCHC(═O)—N(R)(R) claim 47 , OCHC(═O)—N(R)—(CH)—N(R)(R) or O(CH)—N(R)—C(═NR)[N(R)(R)] wherein R claim 47 , R claim 47 , Rand Rare each claim 47 , independently claim 47 , H or C-Calkyl.51. The composition of claim 47 , wherein G is F claim 47 , OCH claim 47 , O(CH)—OCH claim 47 , OCHC(═O)—N(H)CHor OCHC(═O)—N(H)—(CH)—N(CH).52. The composition of claim 47 , wherein g is 1.53. The composition of claim 47 , wherein each of q claim 47 , q claim 47 , qand qis claim 47 , independently claim 47 , H claim 47 , hydroxyl claim 47 , protected hydroxyl claim 47 , O—C-Calkyl claim 47 , substituted O—C-Calkyl or an optionally protected phosphate moiety.54. The composition of claim 47 , wherein one of q claim 47 , q claim 47 , qand qis F claim 47 , O—P(═O)(OH)(OH) claim 47 , O—C- ...

Подробнее
18-02-2016 дата публикации

MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION

Номер: US20160046945A1
Принадлежит: Isis Pharmaceuticals, Inc.

Disclosed herein are antisense compounds and methods for decreasing HBV mRNA, DNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate HBV-related diseases, disorders or conditions. 1. A single stranded modified oligonucleotide consisting of 20 to 30 linked nucleosides and having a nucleobase sequence comprising any of the nucleobase sequences of SEQ ID NOs: 321-331 , 333 , 352-362 , 365-375 , 378 , 379 , 433 , 491-497 , 511-513 , 515 , 605-629 , 632-634 , 650-666 , 700-708 , 742-746 , 770 , 771 , 774-777 , 811 , 918 , 919 , 924-926 , 928 , 947 , 948 , 950-956 , 971 , 972 , 974-982 , 995 , 997-1004 , 1055-1063 , 1067-1105 , 1119-1132 , 1145 , 1147-1161 , 1180-1185 , 1188-1205 , 1207-1223 , 1236-1241 , 1255-1258 , 1271 , or 1272.2. The single stranded modified oligonucleotide of claim 1 , wherein said modified oligonucleotide is at least 96% complementary to SEQ ID NO: 1.35-. (canceled)6. The single stranded modified oligonucleotide of claim 1 , wherein said modified oligonucleotide is 100% complementary to SEQ ID NO: 1.7. (canceled)8. The single stranded modified oligonucleotide of claim 1 , wherein at least one internucleoside linkage is a modified internucleoside linkage.9. The compound of claim 8 , wherein each internucleoside linkage is a phosphorothioate internucleoside linkage.10. The single stranded modified oligonucleotide of claim 1 , wherein at least one nucleoside of the modified oligonucleotide comprises a modified sugar.11. The single stranded modified oligonucleotide of claim 10 , wherein the at least one modified sugar is a bicyclic sugar.12. The single stranded modified oligonucleotide of claim 10 , wherein at least one modified sugar comprises a 2′-O-methoxyethyl group.13. The single stranded modified oligonucleotide of claim 10 , wherein the modified sugar comprises a 2′-O(CH)—OCHgroup.14. The single stranded modified oligonucleotide of claim 10 , wherein the modified sugar comprises a 4′-CH( ...

Подробнее
15-02-2018 дата публикации

COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION

Номер: US20180044676A1
Принадлежит: Ionis Pharmaceuticals, Inc.

Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine. 2. The compound of claim 1 , wherein the modified oligonucleotide comprises at least one modified sugar.3. The compound of claim 2 , wherein at least one modified sugar is a bicyclic sugar.4. The compound of claim 2 , wherein at least one modified sugar comprises a 2′-O-methoxyethyl claim 2 , a constrained ethyl claim 2 , a 3′-fluoro-HNA or a 4′-(CH)—O-2′ bridge claim 2 , wherein n is 1 or 2.5. The compound of claim 2 , wherein at least one modified sugar is 2′-O-methoxyethyl.6. The compound of claim 1 , wherein at least one nucleoside comprises a modified nucleobase.7. The compound of claim 6 , wherein the modified nucleobase is a 5-methylcytosine.8. The compound of claim 1 , wherein the conjugate group is linked to the modified oligonucleotide at the 5′ end of the modified oligonucleotide.9. The compound of claim 1 , wherein the conjugate group is linked to the modified oligonucleotide at the 3′ end of the modified oligonucleotide.10. The compound of claim 1 , wherein each internucleoside linkage of the modified oligonucleotide is selected from a phosphodiester internucleoside linkage and a phosphorothioate internucleoside linkage.11. The compound of claim 10 , wherein the modified oligonucleotide comprises at least 5 phosphodiester internucleoside linkages.12. The compound of claim 10 , wherein the modified oligonucleotide comprises at least two phosphorothioate internucleoside linkages.13. The compound of claim 1 , wherein the modified oligonucleotide is single-stranded.14. The compound of claim 1 , wherein the modified oligonucleotide is double stranded.15. The compound of claim 1 , wherein the modified oligonucleotide comprises:a gap segment consisting of linked deoxynucleosides;a 5′ wing segment consisting of linked nucleosides;a 3′ wing segment consisting of linked nucleosides;wherein the gap segment is ...

Подробнее
19-02-2015 дата публикации

SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF

Номер: US20150051389A1
Принадлежит: Isis Pharmaceuticals, Inc.

Disclosed are oligomeric compounds which are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. The hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell. 1272.-. (canceled)273. A oligomeric compound comprising a modified oligonucleotide consisting of 10 to 30 linked nucleosides , wherein the modified oligonucleotide has a modification motif comprising:a 5′-region consisting of 2-8 linked 5′-region nucleosides, each independently selected from among a modified nucleoside and an unmodified deoxynucleoside, provided that at least one 5′-region nucleoside is a modified nucleoside and wherein the 3′-most 5′-region nucleoside is a modified nucleoside;a 3′-region consisting of 2-8 linked 3′-region nucleosides, each independently selected from among a modified nucleoside and an unmodified deoxynucleoside, provided that at least one 3′-region nucleoside is a modified nucleoside and wherein the 5′-most 3′-region nucleoside is a modified nucleoside; anda central region between the 5′-region and the 3′-region consisting of 6-12 linked central region nucleosides, each independently selected from among: a modified nucleoside and an unmodified deoxynucleoside, wherein the 5′-most central region nucleoside is an unmodified deoxynucleoside and the 3′-most central region nucleoside is an unmodified deoxynucleoside;wherein the modified oligonucleotide has a nucleobase sequence complementary to the nucleobase sequence of a target region of a target nucleic acid.274. The oligomeric compound of claim 273 , wherein the 5′-region has a motif selected from among: AB claim 273 , ABB claim 273 , AAA claim 273 , BBB claim 273 , BBBAA claim 273 , AAB claim 273 , BAA claim 273 , BBAA claim 273 , AABB claim 273 , AAAB claim 273 , ABBW claim 273 , ABBWW claim 273 , ABBB claim 273 , ABBBB claim 273 , ABAB claim 273 , ABABAB claim 273 , ABABBB claim 273 , ABABAA claim 273 , AAABB ...

Подробнее
03-03-2022 дата публикации

MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION

Номер: US20220064650A1
Принадлежит:

Disclosed herein are antisense compounds and methods for decreasing HBV mRNA, DNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate HBV-related diseases, disorders or conditions.

Подробнее
25-02-2021 дата публикации

Conjugated antisense compounds and their use

Номер: US20210052631A1
Принадлежит: Ionis Pharmaceuticals Inc

Provided herein are oligomeric compounds comprising a modified oligonucleotide and a conjugate group for modulating the amount or activity of a target nucleic acid in extra hepatic tissues and extra hepatic cells. Also provided herein are methods of modulating the amount or activity of an extra-hepatic nucleic acid target in a cell comprising contacting the cell with the oligomeric compound or antisense compound.

Подробнее
25-02-2016 дата публикации

COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION

Номер: US20160053261A1
Принадлежит: Isis Pharmaceuticals, Inc.

The present invention provides compositions comprising at least one oligomeric compound comprising an alternating motif and further include a region that is complementary to a nucleic acid target. The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes. In preferred embodiments the compositions of the present invention hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. The present invention also provides methods for modulating gene expression. 1105.-. (canceled)106. A composition comprising a first oligomeric compound and a second oligomeric compound , wherein:at least a portion of said first oligomeric compound is capable of hybridizing with at least a portion of said second oligomeric compound;at least a portion of said first oligomeric compound is complementary to and capable of hybridizing to a selected nucleic acid target;{'sub': '3', 'at least one of said first and said second oligomeric compounds comprises at least nucleosides of a first type (F) and nucleosides of a second type (S); said first and said second types of nucleosides differ in at least one aspect from one another in that they have different 2′-substituent groups; wherein the 2′substituent groups of said first type of nucleosides and said second type of nucleosides are independently selected as —F or —O—CH;'}{'sub': n', 'nn, 'at least one of said first or second oligomeric compounds comprise at least one motif selected from F(SF)Swhere n is from 2 to about 20 and nn is 0 or 1; and'}said first and said second oligomeric compounds are a complementary pair of siRNA oligonucleotides.107. The composition of wherein said first oligomeric compound further comprises a 5′-phosphate group.108. The composition of wherein said second oligomeric compound further comprises a 5′-phosphate group.109. The composition of wherein the nucleosides of each of said first and said second oligomeric compounds ...

Подробнее
25-02-2021 дата публикации

CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE

Номер: US20210054017A1
Принадлежит:

Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the gomeric compounds are conjugated to N-Acetylgalactosamine or to N-Acetylgalactosamine anaologues. 1243-. (canceled)247. The compound of claim 245 , wherein Qis CH.248. The compound of claim 244 , wherein Ris CHN.249. The compound of claim 248 , wherein Qis CH.252. The compound of claim 250 , wherein Ris CHOH.254. The compound of wherein L comprises a phosphorus linking group claim 244 , NH claim 244 , or N(CH).256. The compound of claim 244 , wherein the oligomer is a modified oligonucleotide comprising at least one modified nucleoside comprising a modified base and/or a modified sugar moiety.257. The compound of having at least one modified nucleoside comprising a modified sugar moiety selected from a bicyclic sugar moiety and a 2′-substituted sugar moiety.258. The compound of claim 257 , comprising at least one 4′-C(CH)H—O-2′ or 4′-CH—O-2′bridged bicyclic sugar moiety.259. The compound of comprising at least one 2′-O(CH)OCHsubstituted sugar moiety.260. The compound of claim 244 , wherein the conjugate group is attached to the 5′-terminal nucleoside of the oligomer.261. The compound of claim 244 , wherein the conjugate group is attached to the 3′-terminal nucleoside of the oligomer.262. The compound of claim 244 , wherein the oligomer is an oligonucleotide and has a sugar motif comprising:a 5′-region consisting of 2-8 linked 5′-region nucleosides, wherein at least two 5′-region nucleosides are modified nucleosides and wherein the 3′-most 5′-region nucleoside is a modified nucleoside;a 3′-region consisting of 2-8 linked 3′-region nucleosides, wherein at least two 3′-region nucleosides are modified nucleosides and wherein the 5′-most 3′-region nucleoside is a modified nucleoside; anda central region between the 5′-region and the 3′-region consisting of 5-10 linked central region nucleosides, each independently selected from among: a modified nucleoside and an unmodified ...

Подробнее
13-02-2020 дата публикации

COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION

Номер: US20200048638A1
Принадлежит: Ionis Pharmaceuticals, Inc.

The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject. 1263-. (canceled)265. The modified single-stranded oligonucleotide covalently attached to a conjugate group of claim 264 , wherein the modified single-stranded oligonucleotide consists of 20 to 30 linked nucleosides and has a nucleobase sequence comprising the nucleobase sequence of any of SEQ ID NOs: 455 claim 264 , 453 claim 264 , 448 claim 264 , 237 claim 264 , 444 claim 264 , 450 claim 264 , 228 claim 264 , or 198.266. The modified single-stranded oligonucleotide covalently attached to a conjugate group of claim 264 , wherein the modified single-stranded oligonucleotide consists of the nucleobase sequence of any of SEQ ID NOs: 455 claim 264 , 453 claim 264 , 448 claim 264 , 237 claim 264 , 444 claim 264 , 450 claim 264 , 228 claim 264 , 549 or 198.267. The modified single-stranded oligonucleotide covalently attached to a conjugate group of claim 264 , wherein the modified single-stranded oligonucleotide has:a gap segment consisting of linked deoxynucleosides;a 5′ wing segment consisting of linked nucleosides; anda 3′ wing segment consisting of linked nucleosides;wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.268. The modified single-stranded oligonucleotide covalently attached to a conjugate group of claim 264 , wherein the modified single-stranded oligonucleotide consists of 20 linked nucleosides and has a nucleobase sequence consisting of the nucleobase sequence of any of SEQ ID NOs: 455 claim 264 , 453 claim 264 , 448 claim 264 , 237 claim 264 , 444 claim 264 , 450 claim 264 , 228 claim 264 , or 198 claim 264 , and wherein the modified single-stranded oligonucleotide has:a gap ...

Подробнее
26-02-2015 дата публикации

COMPOUNDS AND METHODS FOR MODULATING EXPRESSION APOB

Номер: US20150057329A1
Принадлежит: Isis Pharmaceuticals, Inc.

The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing. 1. A short antisense compound 8 to 16 monomers in length , comprising a 2′-deoxyribonucleotide gap region flanked on each side by a wing , wherein each wing independently comprises 1 to 3 high-affinity modified monomers and wherein the short antisense compound is targeted to a nucleotide encoding ApoB.2. The short antisense compound of claim 1 , wherein said high-affinity modified monomers are sugar-modified nucleotides.3. The short antisense compound of claim 2 , wherein at least one of the sugar-modified nucleotides comprises a bridge between the 4′ and the 2′ position of the sugar.4. The short antisense compound of claim 2 , wherein each of said high-affinity modified nucleotides confers a ΔTof 1 to 4 degrees per nucleotide.5. The short antisense compound of claim 2 , wherein each of said sugar-modified nucleotides comprises a 2′-substituent group that is other than H or OH.6. The short antisense compound of claim 5 , wherein at least one of said sugar-modified nucleotides is a 4′ to 2′ bridged bicyclic nucleotide.7. The short antisense compound of claim 5 , wherein each of the 2′-substituent groups is claim 5 , independently claim 5 , alkoxy claim 5 , substituted alkoxy claim 5 , or halogen.8. The short antisense ...

Подробнее
21-02-2019 дата публикации

COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION

Номер: US20190055554A1
Принадлежит: Ionis Pharmaceuticals, Inc.

Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine. 125-. (canceled)27. The compound of claim 26 , wherein the modified oligonucleotide comprises at least one modified sugar.28. The compound of claim 27 , wherein at least one modified sugar is a bicyclic sugar.29. The compound of claim 27 , wherein at least one modified sugar comprises a 2′-O-methoxyethyl claim 27 , a constrained ethyl claim 27 , or a 4′-(CH)—O-2′ bridge claim 27 , wherein n is 1 or 2.30. The compound of claim 27 , wherein at least one modified sugar is 2′-O-methoxyethyl.31. The compound of claim 26 , wherein at least one nucleoside comprises a modified nucleobase.32. The compound of claim 31 , wherein the modified nucleobase is a 5-methylcytosine.33. The compound of claim 26 , wherein the conjugate group is linked to the modified oligonucleotide at the 5′ end of the modified oligonucleotide.34. The compound of claim 26 , wherein the conjugate group is linked to the modified oligonucleotide at the 3′ end of the modified oligonucleotide.35. The compound of claim 26 , wherein each internucleoside linkage of the modified oligonucleotide is selected from a phosphodiester internucleoside linkage and a phosphorothioate internucleoside linkage.36. The compound of claim 35 , wherein the modified oligonucleotide comprises at least 5 phosphodiester internucleoside linkages.37. The compound of claim 35 , wherein the modified oligonucleotide comprises at least two phosphorothioate internucleoside linkages.38. The compound of claim 26 , wherein the modified oligonucleotide is single-stranded.39. The compound of claim 26 , wherein the modified oligonucleotide is double stranded.40. The compound of claim 26 , wherein the modified oligonucleotide comprises:a gap segment consisting of linked deoxynucleosides;a 5′ wing segment consisting of linked nucleosides;a 3′ wing segment consisting of linked nucleosides;wherein ...

Подробнее
20-02-2020 дата публикации

COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION

Номер: US20200056185A1
Принадлежит: Ionis Pharmaceuticals, Inc.

Disclosed herein are antisense compounds and methods for decreasing PKK mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate PKK-associated diseases, disorders, and conditions. 1219.-. (canceled)220. A compound comprising a modified oligonucleotide and a conjugate group , wherein the modified oligonucleotide consists of 12 to 30 linked nucleosides and has a nucleobase sequence comprising a portion of at least 15 contiguous nucleobases that is at least 90% complementary to an equal length portion of nucleobases 33183-33242 of SEQ ID NO: 10 , and wherein the conjugate group comprises at least one N-Acetylgalactosamine (GalNAc).221. The compound of claim 220 , wherein the portion of at least 15 contiguous nucleobases is 100% complementary to the equal length portion of nucleobases 33183-33242 of SEQ ID NO: 10.222. The compound of claim 220 , wherein the sequence of the modified oligonucleotide is SEQ ID NO: 705.223. The compound of claim 220 , wherein the conjugate group comprises three GalNAcs.225. The compound of claim 224 , consisting of the modified oligonucleotide and the conjugate group.226. The compound of claim 220 , wherein the modified oligonucleotide consists of 20 linked nucleosides.227. The compound of claim 220 , wherein the modified oligonucleotide is at least 90% complementary to SEQ ID NO: 10.228. The compound of claim 220 , wherein at least one internucleoside linkage of the modified oligonucleotide is a phosphorothioate linkage.229. The compound of claim 220 , wherein each cytosine of the modified oligonucleotide is a 5′-methylcytosine.230. The compound of claim 220 , wherein the modified oligonucleotide is single-stranded.231. The compound of claim 220 , comprising at least one 2′-O-methoxyethyl nucleoside claim 220 , 2′-O-methyl nucleoside claim 220 , constrained ethyl nucleoside claim 220 , LNA nucleoside claim 220 , or 3′-fluoro-HNA nucleoside.232. The compound of claim 220 , wherein ...

Подробнее
20-02-2020 дата публикации

SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF

Номер: US20200056187A1
Принадлежит: Ionis Pharmaceuticals, Inc.

The present disclosure provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell. In certain embodiments, certain oligomeric compounds selectively reduce the expression of a target nucleic acid transcript relative to a non-target nucleic acid transcript. 1168.-. (canceled)169. A oligomeric compound comprising a modified oligonucleotide consisting of 10 to 30 linked nucleosides , wherein the modified oligonucleotide has a modification motif comprising: a 5′-region consisting of 1-9 linked 5′-region nucleosides , each independently selected from among a modified nucleoside and an unmodified deoxynucleoside , provided that at least one 5′-region nucleoside is a modified nucleoside and wherein the 3′-most 5′-region nucleoside is a modified nucleoside;a 3′-region consisting of 2-10 linked 3′-region nucleosides, wherein each 3′-region nucleoside comprises a modified nucleoside; anda central region between the 5′-region and the 3′-region consisting of 6-10 linked central region nucleosides, each independently selected from among: a modified nucleoside and an unmodified deoxynucleoside, wherein the 5′-most central region nucleoside is an unmodified deoxynucleoside and the 3′-most central region nucleoside is an unmodified deoxynucleoside; and wherein the modified oligonucleotide has a nucleobase sequence complementary to the nucleobase sequence of a target region of a nucleic acid associated with a huntingtin transcript;wherein the nucleobase sequence of the target region of the target nucleic acid differs from the nucleobase sequence of at least one non-target nucleic acid by a single differentiating nucleobase; and wherein the single differentiating nucleobase is a single-nucleotide polymorphism selected from among ...

Подробнее
28-02-2019 дата публикации

METHODS AND COMPOSITIONS FOR INHIBITING PMP22 EXPRESSION

Номер: US20190062741A1
Принадлежит: Ionis Pharmaceuticals, Inc.

The present embodiments provide methods, compounds, and compositions useful for inhibiting PMP22 expression and for treating, preventing, or ameliorating a disease associated with PMP22. 1. A method of treating , preventing , or ameliorating Charcot-Marie-Tooth Disease in an individual comprising administering to the individual an oligomeric compound comprising a modified oligonucleotide , and thereby treating , preventing , or ameliorating Charcot-Marie-Tooth Disease.2. A method of treating , preventing , or ameliorating a disease associated with PMP22 in an individual comprising administering to the individual an oligomeric compound comprising a modified oligonucleotide , and thereby treating , preventing , or ameliorating the disease.3. A method comprising administering an oligomeric compound comprising a modified oligonucleotide to an individual for treating , preventing , or ameliorating Charcot-Marie-Tooth Disease , and thereby treating , preventing , or ameliorating Charcot-Marie-Tooth Disease.4. A method comprising administering an oligomeric compound comprising a modified oligonucleotide to an individual for treating , preventing , or ameliorating a disease associated with PMP22 , and thereby treating , preventing , or ameliorating the disease.5. A method of reducing the amount or activity of a PMP22 transcript in a nerve of an individual having , or at risk of having , a disease associated with PMP22 comprising administering an oligomeric compound comprising a modified oligonucleotide , and thereby reducing the amount or activity of a PMP22 transcript in the nerve of the individual.6. The method of claim 5 , wherein the amount or activity of a PMP22 transcript is reduced in Schwann cells of the individual.7. The method of any of - claim 5 , wherein the individual exhibits at least one symptom of Charcot-Marie-Tooth Disease.8. The method of any of - claim 5 , wherein the individual is a mammal9. The method of any of - claim 5 , wherein the individual is a ...

Подробнее
28-02-2019 дата публикации

Oligomeric Compounds and Compositions for use in Modulation of Small Non-Coding RNAs

Номер: US20190062744A1
Принадлежит: REGULUS THERAPEUTICS INC.

Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided. 12-. (canceled)3. A method of inhibiting the activity of miR-10b , comprising contacting a cell comprising miR-10b with a compound comprising an oligonucleotide , wherein:the oligonucleotide is at least 90% complementary to miR-10b (SEQ ID NO: 199);the oligonucleotide consists of 15 to 30 linked monomeric subunits; andat least one monomeric subunit comprises a modified sugar moiety.4. The method of claim 3 , wherein the oligonucleotide is at least 95% complementary to miR-10b.5. The method of claim 3 , wherein the oligonucleotide is 100% complementary to miR-10b.6. The method of claim 3 , wherein the oligonucleotide consists of 18 claim 3 , 19 claim 3 , 20 claim 3 , 21 claim 3 , or 22 linked monomeric subunits.7. The method of claim 3 , wherein each modified sugar moiety is independently selected from 2′-F claim 3 , 2′-O-methyl claim 3 , 2′-O-methoxyethyl claim 3 , and a bicyclic sugar moiety.8. The method of claim 7 , wherein the bicyclic sugar moiety comprises a 4′-CH—O-2′ bridge.9. The method of claim 3 , wherein the oligonucleotide comprises at least one modified internucleoside linkage.10. The method of claim 3 , wherein each internucleoside linkage of the oligonucleotide is a phosphorothioate linkage.11. The method of claim 3 , wherein each monomeric subunit comprises a modified sugar moiety.12. The method of claim 11 , wherein each modified sugar moiety is independently selected from 2′-F claim 11 , 2′-O-methyl claim 11 , 2′-O-methoxyethyl claim 11 , and a bicyclic sugar moiety.13. The method of claim 12 , wherein the bicyclic sugar moiety comprises ...

Подробнее
11-03-2021 дата публикации

COMPOSITIONS FOR MODULATING TAU EXPRESSION

Номер: US20210071176A1
Принадлежит: Biogen MA Inc.

Disclosed herein are antisense compounds and methods for decreasing Tau mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Tau-associated diseases, disorders, and conditions. 1. (canceled)2. (canceled)3. (canceled)4. (canceled)5. (canceled)6. (canceled)7. (canceled)8. (canceled)9. A compound , comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides and having a nucleobase sequence comprising at least 8 , at least 9 , at least 10 , at least 11 , at least 12 , at least 13 , at least 14 , at least 15 , at least 16 , at least 17 , at least 18 , at least 19 , or at least 20 consecutive nucleobases of any of the nucleobase sequences of SEQ ID NOs: 20-2565.10. A compound , comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides and comprising a nucleobase sequence comprising at least 8 , at least 9 , at least 10 , at least 11 , at least 12 , at least 13 , at least 14 , at least 15 , at least 16 , at least 17 , at least 18 , at least 19 , or at least 20 consecutive nucleobases complementary to an equal length portion of nucleobases:(i) 135783-135980 of SEQ ID NO: 1;(ii) 135853-135872 of SEQ ID NO: 1;(iii) 135783-135929 of SEQ ID NO: 1, or(iv) 135783-135914 of SEQ ID NO: 1.11. (canceled)12. (canceled)13. (canceled)14. (canceled)15. The compound of claim 9 , consisting of a single-stranded modified oligonucleotide.16. The compound of claim 9 , wherein at least one internucleoside linkage is a modified internucleoside linkage.17. (canceled)18. (canceled)19. (canceled)20. (canceled)21. (canceled)22. (canceled)23. (canceled)24. (canceled)25. (canceled)26. The compound of claim 9 , wherein at least one internucleoside linkage is a phosphorothioate linkage and at least one internucleoside linkage is a phosphodiester linkage.27. (canceled)28. The compound of claim 9 , wherein at least one nucleoside comprises a modified nucleobase.29. (canceled)30. The compound of claim 9 ...

Подробнее
17-03-2016 дата публикации

COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION

Номер: US20160076030A1
Принадлежит: Isis Pharmaceuticals, Inc.

Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine. 2. (canceled)3. The compound of claim 1 , wherein the modified oligonucleotide comprises at least one modified sugar.4. The compound of claim 3 , wherein at least one modified sugar is a bicyclic sugar.5. The compound of claim 3 , wherein at least one modified sugar comprises a 2′-O-methoxyethyl claim 3 , a constrained ethyl claim 3 , a 3′-fluoro-HNA or a 4′-(CH)—O-2′ bridge claim 3 , wherein n is 1 or 2.6. The compound of claim 3 , wherein at least one modified sugar is 2′-O-methoxyethyl.7. The compound of claim 1 , wherein at least one nucleoside comprises a modified nucleobase.8. The compound of claim 7 , wherein the modified nucleobase is a 5-methylcytosine.9. The compound of claim 1 , wherein the conjugate group is linked to the modified oligonucleotide at the 5′ end of the modified oligonucleotide.10. The compound of claim 1 , wherein the conjugate group is linked to the modified oligonucleotide at the 3′ end of the modified oligonucleotide.11. The compound of claim 1 , wherein each internucleoside linkage of the modified oligonucleotide is selected from a phosphodiester internucleoside linkage and a phosphorothioate internucleoside linkage.12. The compound of claim 11 , wherein the modified oligonucleotide comprises at least 5 phosphodiester internucleoside linkages.13. The compound of claim 11 , wherein the modified oligonucleotide comprises at least two phosphorothioate internucleoside linkages.14. The compound of claim 1 , wherein the modified oligonucleotide is single-stranded.15. The compound of claim 1 , wherein the modified oligonucleotide is double stranded.16. The compound of claim 1 , wherein the modified oligonucleotide comprises:a gap segment consisting of linked deoxynucleosides;a 5′ wing segment consisting of linked nucleosides;a 3′ wing segment consisting of linked nucleosides;wherein the gap ...

Подробнее
17-03-2016 дата публикации

PHOSPHOROUS-LINKED OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE MODULATION

Номер: US20160076031A1
Принадлежит: Isis Pharmaceuticals, Inc.

Oligonucleotide compositions comprising first and second oligonucleotides are provided wherein at least a portion of the first oligonucleotide is capable of hybridizing with at least a portion of the second oligonucleotide, at least a portion of the first oligonucleotide is complementary to and capable of hybridizing to a selected target nucleic acid, and at least one of the first or second oligonucleotides includes at least one nucleotide having a modified phosphorous-containing internucleoside linkage. Oligonucleotide/protein compositions are also provided comprising an oligonucleotide complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex (RISC), wherein at least one nucleotide of the oligonucleotide has a modified phosphorous-containing internucleoside linkage. 153-. (canceled)54. A composition comprising a first oligomer and a second oligomer , wherein:at least a portion of said first oligomer is capable of hybridizing with at least a portion of said second oligomer,at least a portion of first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid, and a phosphorothioate; phosphorodithioate; phosphonate; phosphonothioate; phosphotriester; phosphorothiotriester; phosphoramidate; phosphorothioamidate; phosphinate; boronate; α-D-arabinofuranosyl; or 2′-5′ internucleoside linkage; or', 'at least one of said first or said second oligomers contains at least one region of chirally pure internucleoside linkages or includes at least one region of inverted polarity., 'at least one of said first or said second oligomers includes at least one nucleotide having a modification comprising55. The composition of wherein each of said first and second oligomers has 12 to 30 nucleobases.56. The composition of wherein said at least one nucleotide having a modification comprises a 2′-5′ internucleoside linkage.58. The composition of ...

Подробнее
17-03-2016 дата публикации

COMPOSITIONS AND METHODS

Номер: US20160076032A1
Принадлежит: Isis Pharmaceuticals, Inc.

Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine. 1. A compound comprising a modified oligonucleotide and a conjugate group , wherein the modified oligonucleotide consists of 8 to 80 linked nucleosides and has a nucleobase sequence at least 85% , 90% , 95% , or 100% complementary to SEQ ID NO: 1.2. The compound of claim 1 , wherein the nucleobase sequence of the modified oligonucleotide is complementary within nucleobases 3291-3310 claim 1 , 3290-3309 claim 1 , 3287-3306 claim 1 , or 3292-3311 of SEQ ID NO: 1 claim 1 , and wherein said modified oligonucleotide is at least 85% claim 1 , 90% claim 1 , 95% claim 1 , or 100% complementary to SEQ ID NO: 1.3. The compound of claim 1 , wherein the modified oligonucleotide consists of 10 to 30 linked nucleosides and has a nucleobase sequence comprising at least 8 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 54 claim 1 , 55 claim 1 , 56 claim 1 , or 57.4. The compound of claim 3 , wherein the modified oligonucleotide has a nucleobase sequence comprising the sequence recited in SEQ ID NOs: 54 claim 3 , 55 claim 3 , 56 claim 3 , or 57.5. The compound of claim 3 , wherein the modified oligonucleotide has a nucleobase sequence consisting of the sequence recited in SEQ ID NOs: 54 claim 3 , 55 claim 3 , 56 claim 3 , or 57.6. A compound comprising a modified oligonucleotide and a conjugate group claim 3 , wherein the modified oligonucleotide consists of 8 to 80 linked nucleosides and has a nucleobase sequence at least 85% claim 3 , 90% claim 3 , 95% claim 3 , or 100% complementary to SEQ ID NO: 1.7. The compound of claim 1 , wherein the nucleobase sequence of the modified oligonucleotide is complementary within nucleobases 3291-3310 claim 1 , 3290-3309 claim 1 , 3287-3306 claim 1 , or 3292-3311 of SEQ ID NO: 1 claim 1 , and wherein said modified oligonucleotide is at least 85% claim 1 , 90% claim 1 , ...

Подробнее
18-03-2021 дата публикации

Modulators of PCSK9 Expression

Номер: US20210077630A1
Принадлежит: Ionis Pharmaceuticals Inc

The present embodiments provide methods, compounds, and compositions useful for inhibiting PCSK9 expression, which may be useful for treating, preventing, or ameliorating a disease associated with PCSK9.

Подробнее
25-03-2021 дата публикации

COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION

Номер: US20210087566A1
Принадлежит:

Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof. 2. The compound of claim 1 , wherein the modified oligonucleotide consists of 20 linked nucleosides.3. The compound of claim 1 , wherein the modified oligonucleotide comprises at least one modified sugar.4. The compound of claim 3 , wherein at least one modified sugar is a bicyclic sugar.5. The compound of claim 3 , wherein at least one modified sugar comprises a 2′-O-methoxyethyl claim 3 , a constrained ethyl claim 3 , a 3′-fluoro-HNA or a 4′-(CH)—O-2′ bridge claim 3 , wherein n is 1 or 2.6. The compound of claim 3 , wherein at least one modified sugar is 2′-O-methoxyethyl.7. The compound of claim 1 , wherein at least one nucleoside comprises a modified nucleobase.8. The compound of claim 7 , wherein the modified nucleobase is a 5-methylcytosine.9. The compound of claim 1 , wherein the conjugate group is linked to the modified oligonucleotide at the 5′ end of the modified oligonucleotide.10. The compound of claim 1 , wherein the conjugate group is linked to the modified oligonucleotide at the 3′ end of the modified oligonucleotide.11. The compound of claim 1 , wherein each internucleoside linkage of the modified oligonucleotide is selected from a phosphodiester internucleoside linkage and a phosphorothioate internucleoside linkage.12. The compound of claim ...

Подробнее
31-03-2016 дата публикации

COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION

Номер: US20160090595A1
Принадлежит: Isis Pharmaceuticals, Inc.

Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein C-III (ApoCIII). In certain embodiments, the ApoCIII targeting oligomeric compounds are conjugated to N-Acetylgalactosamine Also disclosed herein are conjugated oligomeric compounds targeting ApoCIII for use in decreasing ApoCIII to treat, prevent, or ameliorate diseases, disorders or conditions related to ApoCIII. Certain diseases, disorders or conditions related to ApoCIII include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof. 2. The compound of claim 1 , wherein the modified oligonucleotide consists of 20 linked nucleosides.3. The compound of claim 1 , wherein the modified oligonucleotide comprises at least one modified sugar.4. The compound of claim 3 , wherein at least one modified sugar is a bicyclic sugar.5. The compound of claim 3 , wherein at least one modified sugar comprises a 2′-O-methoxyethyl claim 3 , a constrained ethyl claim 3 , a 3′-fluoro-HNA or a 4′-(CH)—O-2′ bridge claim 3 , wherein n is 1 or 2.6. The compound of claim 3 , wherein at least one modified sugar is 2′-O-methoxyethyl.7. The compound of claim 1 , wherein at least one nucleoside comprises a modified nucleobase.8. The compound of claim 7 , wherein the modified nucleobase is a 5-methylcytosine.9. The compound of claim 1 , wherein the conjugate group is linked to the modified oligonucleotide at the 5′ end of the modified oligonucleotide.10. The compound of claim 1 , wherein the conjugate group is linked to the modified oligonucleotide at the 3′ end of the modified oligonucleotide.11. The compound of claim 1 , wherein each internucleoside linkage of the modified oligonucleotide is selected from a phosphodiester internucleoside linkage and a phosphorothioate internucleoside linkage.12. The compound of claim 11 , wherein the ...

Подробнее
31-03-2016 дата публикации

COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION

Номер: US20160090596A1
Принадлежит: ISIS PHARMACEUTICALS INC

Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.

Подробнее
05-04-2018 дата публикации

COMPOSITIONS FOR MODULATING TAU EXPRESSION

Номер: US20180094261A1
Принадлежит: Ionis Pharmaceuticals, Inc.

Disclosed herein are antisense compounds and methods for decreasing Tau mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Tau-associated diseases, disorders, and conditions. 1. A compound comprising a modified oligonucleotide consisting of 12 to 50 linked nucleosides and having a nucleobase sequence comprising at least 8 contiguous nucleobases of a sequence selected from among SEQ ID Nos: 20-1698 , SEQ ID Nos: 1704-2443 , and SEQ ID NOs: 2478-2483 , wherein the nucleobase sequence of the modified oligonucleotide is at least 90% complementary to SEQ ID NO: 1.2. The compound of claim 1 , wherein the modified oligonucleotide is a single-stranded oligonucleotide.3. The compound of claim 1 , wherein at least one internucleoside linkage of the modified oligonucleotide is a modified internucleoside linkage.4. The compound of claim 3 , wherein the modified internucleoside linkage is a phosphorothioate internucleoside linkage.5. The compound of claim 4 , wherein at least one internucleoside linkage of the modified oligonucleotide is a phosphodiester internucleoside linkage.6. The compound of claim 1 , wherein at least one nucleobase of the modified oligonucleotide is a modified nucleobase.7. The compound of claim 6 , wherein the modified nucleobase is a 5-methylcytosine.8. The compound of claim 1 , wherein at least one nucleoside of the modified oligonucleotide comprises a modified sugar.9. The compound of claim 8 , wherein the at least one modified sugar is a bicyclic sugar.10. The compound of claim 9 , wherein each bicyclic sugar comprises a chemical bridge between the 4′ and 2′ positions of the sugar claim 9 , wherein each chemical bridge is independently selected from: 4′-CH(R)—O-2′ and 4′-(CH)—O-2′ claim 9 , wherein each R is independently selected from H claim 9 , C-Calkyl and C-Calkoxy.11. The compound of claim 10 , wherein at least one chemical bridge is 4′-CH(R)—O-2′ and wherein R is claim 10 , methyl. ...

Подробнее
23-04-2015 дата публикации

TRICYCLIC NUCLEIC ACID ANALOGS

Номер: US20150112055A1
Принадлежит: Isis Pharmaceuticals, Inc.

The present disclosure provides tricyclic nucleosides and oligomeric compounds prepared therefrom. The tricyclic nucleosides each have a tricyclic ribosyl sugar moiety wherein a bridge between the 2′ and 4′ ribosyl ring carbon atoms further comprises a fused carbocyclic or heterocyclic ring. The tricyclic nucleosides are expected to be useful for enhancing properties of oligomeric compounds including for example binding affinity and nuclease resistance. 2. The compound of wherein Bx is a pyrimidine claim 1 , substituted pyrimidine claim 1 , purine or substituted purine.34-. (canceled)5. The tricyclic nucleoside of wherein n is 1.6. The tricyclic nucleoside of wherein Q is CH═CH or CH—CH.7. (canceled)8. The tricyclic nucleoside of wherein Q is O claim 1 , S or NRwherein Ris H claim 1 , C-Calkyl or substituted C-Calkyl.911-. (canceled)12. The tricyclic nucleoside of wherein Ris methyl.13. (canceled)15. (canceled)16. The tricyclic nucleoside of wherein the tricyclic nucleoside has Formula Ia and qand qare each H or the tricyclic nucleoside has formula Ib and either qand qor qand qare each H.1719-. (canceled)20. The tricyclic nucleoside of wherein one of qand qis a 4 claim 1 ,4′-dimethoxytrityl protected hydroxyl group and one of qand qis diisopropylcyanoethoxy phosphoramidite.22. (canceled)23. The oligomeric compound of wherein each Bx is claim 21 , independently claim 21 , uracil claim 21 , thymine claim 21 , cytosine claim 21 , 5-methylcytosine claim 21 , adenine or guanine for each tricyclic nucleoside having Formula II.24. The oligomeric compound of wherein n is 1 for each tricyclic nucleoside having Formula II.25. The oligomeric compound of wherein each Q is CH═CH.26. The oligomeric compound of wherein each Q is CH—CH.27. The oligomeric compound of wherein each Q is O claim 21 , S or NRwherein Ris H claim 21 , C-Calkyl or substituted C-Calkyl.2830-. (canceled)31. The tricyclic nucleoside of wherein each Ris methyl.33. (canceled)34. The oligomeric compound of ...

Подробнее
19-04-2018 дата публикации

COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSION

Номер: US20180105817A1
Принадлежит: Ionis Pharmaceuticals, Inc.

Disclosed herein are compositions and compounds comprising modified oligonucleotides for modulating TMPRSS6 and modulating an iron accumulation disease, disorder and/or condition in an individual in need thereof. Iron accumulation diseases in an individual such as polycythemia, hemochromatosis or β-thalassemia can be treated, ameliorated, delayed or prevented with the administration of antisense compounds targeted to TMPRSS6. 1. A compound comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides having a nucleobase sequence comprising a portion of at least 8 contiguous nucleobases complementary to an equal length portion of nucleobases 3162 to 3184 of SEQ ID NO: 1 , wherein the nucleobase sequence of the modified oligonucleotide is at least 80% complementary to SEQ ID NO: 1.2. The compound of claim 1 , wherein the modified oligonucleotide consists of 15 to 30 claim 1 , 15 to 25 claim 1 , 15 to 24 claim 1 , 16 to 24 claim 1 , 17 to 24 claim 1 , 18 to 24 claim 1 , 19 to 24 claim 1 , 20 to 24 claim 1 , 19 to 22 claim 1 , 20 to 22 claim 1 , 16 to 20 claim 1 , 16 or 20 linked nucleosides.3. The compound of claim 1 , wherein the modified oligonucleotide comprises a nucleobase sequence comprising a portion of at least 10 claim 1 , least 11 claim 1 , at least 12 claim 1 , least 13 claim 1 , at least 14 claim 1 , least 15 claim 1 , at least 16 claim 1 , least 17 claim 1 , at least 18 claim 1 , at least 19 claim 1 , or at least 20 contiguous nucleobases complementary to an equal length portion of SEQ ID NO: 14. The compound of any preceding claim claim 1 , wherein the nucleobase sequence of the modified oligonucleotide is at least 85% claim 1 , at least 90% claim 1 , at least 95% claim 1 , or 100% complementary to SEQ ID NO: 15. A compound comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides having a nucleobase sequence comprising at least 8 claim 1 , at least 9 claim 1 , at least 10 claim 1 , at least 11 claim 1 , at least 12 ...

Подробнее
05-05-2016 дата публикации

Compositions and methods for modulation of target nucleic acids

Номер: US20160122761A1
Принадлежит: ISIS PHARMACEUTICALS INC

The present disclosure pertains generally to chemically-modified oligonucleotides for use in research, diagnostics, and/or therapeutics. In certain embodiments, the present disclosure describes compounds and methods for the modulation of a target nucleic acid. In certain embodiments, the present disclosure describes compounds and methods for the modulation of Apoliprotein C-III expression.

Подробнее
07-05-2015 дата публикации

CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE

Номер: US20150126718A1
Принадлежит: Isis Pharmaceuticals, Inc.

Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine. 2. The compound of claim 1 , wherein the conjugate linker comprises an amine claim 1 , an amide claim 1 , an ester claim 1 , an ether claim 1 , a pyrrolidine claim 1 , ethylene glycol claim 1 , a polyamide claim 1 , or a disulfide bond.6. The compound of claim 5 , wherein the oligomeric compound is a modified oligonucleotide.7. The compound of claim 6 , wherein the modified oligonucleotide consists of 15 to 24 linked nucleosides wherein at least one nucleoside is a modified nucleoside.8. The compound of claim 6 , wherein the modified oligonucleotide comprises at least one modified nucleoside selected from among: a 2′-MOE nucleoside claim 6 , a 2′-OMe nucleoside claim 6 , a 2′-F nucleoside claim 6 , a (4′-CH—O-2′) bicyclic nucleoside claim 6 , a (4′-(CH)—O-2′) bicyclic nucleoside claim 6 , a (4′-C(CH)H—O-2′) bicyclic nucleoside; and a morpholino.9. The compound of claim 8 , wherein the modified oligonucleotide has a gapmer sugar motif comprising:a 5′-region consisting of 2-8 linked 5′-region nucleosides, wherein each 5′-region nucleoside is a modified nucleoside;a 3′-region consisting of 2-8 linked 3′-region nucleosides, wherein each 3′-region nucleoside is a modified nucleoside; anda central region between the 5′-region and the 3′-region consisting of 5-10 linked central region nucleosides, each independently selected from among: a modified nucleoside and an unmodified deoxynucleoside, wherein the 5′-most central region nucleoside is an unmodified deoxynucleoside and the 3′-most central region nucleoside is an unmodified deoxynucleoside.10. The compound of claim 9 , wherein the modified oligonucleotide has a chemical motif selected from among:{'sub': 0-1', '(3-5), 'MsMy(Ds)(DsDs)MsM'}{'sub': 0-1', '(3-5), 'MsMy(Ds)(DsDs)MyMsM'}{'sub': 0-1', '(3-5), 'MsMy(Ds)(DsDs)MyMyMsM'}{'sub': 0-1', '(3-5), 'MsMy(Ds)(DsDs) ...

Подробнее
07-05-2015 дата публикации

Compositions and methods for modulating apolipoprotein c-iii expression

Номер: US20150126719A1
Принадлежит: ISIS PHARMACEUTICALS INC

Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein C-III (ApoCIII). In certain embodiments, the ApoCIII targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting ApoCIII for use in decreasing ApoCIII to treat, prevent, or ameliorate diseases, disorders or conditions related to ApoCIII. Certain diseases, disorders or conditions related to ApoCIII include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.

Подробнее
07-05-2015 дата публикации

COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION

Номер: US20150126720A1
Принадлежит: Isis Pharmaceuticals, Inc.

Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof. 2. The compound of claim 1 , wherein the modified oligonucleotide consists of 20 linked nucleosides.3. The compound of claim 1 , wherein the modified oligonucleotide comprises at least one modified sugar.4. The compound of claim 3 , wherein at least one modified sugar is a bicyclic sugar.5. The compound of claim 3 , wherein at least one modified sugar comprises a 2′-O-methoxyethyl claim 3 , a constrained ethyl claim 3 , a 3′-fluoro-HNA or a 4′-(CH)—O-2′ bridge claim 3 , wherein n is 1 or 2.6. The compound of claim 3 , wherein at least one modified sugar is 2′-O-methoxyethyl.7. The compound of claim 1 , wherein at least one nucleoside comprises a modified nucleobase.8. The compound of claim 7 , wherein the modified nucleobase is a 5-methylcytosine.9. The compound of claim 1 , wherein the conjugate group is linked to the modified oligonucleotide at the 5′ end of the modified oligonucleotide.10. The compound of claim 1 , wherein the conjugate group is linked to the modified oligonucleotide at the 3′ end of the modified oligonucleotide.11. The compound of claim 1 , wherein each internucleoside linkage of the modified oligonucleotide is selected from a phosphodiester internucleoside linkage and a phosphorothioate internucleoside linkage.12. The compound of claim ...

Подробнее
07-05-2015 дата публикации

5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom

Номер: US20150126725A1
Принадлежит: ISIS PHARMACEUTICALS INC

The present invention provides modified nucleosides and oligomeric compounds prepared therefrom. More particularly, the present invention provides modified nucleosides having at least one 5′-substituent and a 2′-O-substituent, oligomeric compounds comprising at least one of these modified nucleosides and methods of using the oligomeric compounds. In some embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.

Подробнее
01-09-2022 дата публикации

COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION

Номер: US20220275365A9
Принадлежит: Ionis Pharmaceuticals, Inc.

Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine. 133-. (canceled)3539-. (canceled)40. The method of claim 34 , wherein the transthyretin amyloidosis is senile systemic amyloidosis (SSA).41. The method of claim 34 , wherein the transthyretin amyloidosis is familial amyloid polyneuropathy (FAP).42. The method of claim 34 , wherein the transthyretin amyloidosis is familial amyloid cardiopathy (FAC). The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled BIOL0248USC5SEQ_ST25.txt, created on Feb. 13, 2020, which is 20 Kb in size. The information in the electronic format of the sequence listing is incorporated herein by reference in its entirety.The principle behind antisense technology is that an antisense compound hybridizes to a target nucleic acid and modulates the amount, activity, and/or function of the target nucleic acid. For example in certain instances, antisense compounds result in altered transcription or translation of a target. Such modulation of expression can be achieved by, for example, target mRNA degradation or occupancy-based inhibition. An example of modulation of RNA target function by degradation is RNase H-based degradation of the target RNA upon hybridization with a DNA-like antisense compound. Another example of modulation of gene expression by target degradation is RNA interference (RNAi). RNAi refers to antisense-mediated gene silencing through a mechanism that utilizes the RNA-induced siliencing complex (RISC). An additional example of modulation of RNA target function is by an occupancy-based mechanism such as is employed naturally by microRNA. MicroRNAs are small non-coding RNAs that regulate the expression of protein-coding RNAs. The binding of an antisense compound to a microRNA prevents that microRNA from binding to its messenger RNA targets, and ...

Подробнее
02-05-2019 дата публикации

SINGLE-STRANDED RNAI OLIGONUCLEOTIDES TARGETING APOC-III

Номер: US20190127737A1
Принадлежит: Ionis Pharmaceuticals, Inc.

The present disclosure pertains generally to chemically-modified oligonucleotides for use in research, diagnostics, and/or therapeutics. In certain embodiments, the present disclosure describes compounds and methods for the modulation of a target nucleic acid. In certain embodiments, the present disclosure describes compounds and methods for the modulation of Apoliprotein C-III expression. 1209.-. (canceled)210. A compound comprising a single stranded oligonucleotide consisting of 18 to 23 linked nucleosides and having a nucleobase sequence having a hybridizing region and a 3′-terminal region , wherein said hybridizing region comprises at least 18 contiguous nucleobases 100% complementary to an equal-length portion within a target region of an Apolipoprotein C-III transcript , wherein the hybridizing region has the nucleobase sequence of the hybridizing region of SEQ ID NO: 3; wherein the 5′-terminal nucleoside of the single-stranded oligonucleotide comprises a stabilized phosphate moiety and an internucleoside linking group linking the 5′-terminal nucleoside to the remainder of the oligonucleotide; and wherein the phosphorus atom of the stabilized phosphate moiety is attached to the 5′-terminal nucleoside through a phosphorus-carbon bond.211. The compound of claim 210 , wherein the single stranded oligonucleotide has a nucleobase sequence of SEQ ID NO: 3.214. The compound of claim 213 , wherein each of Qand Qis H.215. The compound of claim 212 , wherein Ris O and Rand Rare each claim 212 , independently selected from among: OCH claim 212 , OCHCH claim 212 , OCH(CH).217. The compound of claim 210 , wherein each nucleoside of the remainder of the oligonucleotide is a RNA-like nucleoside.218. The compound of claim 216 , wherein each RNA-like nucleoside is selected from among: 2′-F claim 216 , 2′-MOE claim 216 , 2′-OMe claim 216 , LNA claim 216 , F-HNA claim 216 , and cEt.219. The compound of claim 217 , wherein the remainder of the oligonucleotide comprises at least ...

Подробнее